

(51) International Patent Classification ⁵ : A61K 31/135, 37/02		A1	(11) International Publication Number: WO 94/12162
			(43) International Publication Date: 9 June 1994 (09.06.94)
(21) International Application Number: PCT/FI93/00514		(81) Designated States: AT, AU, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KR, LU, LV, NL, NO, NZ, PL, PT, RU, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 1 December 1993 (01.12.93)			
(30) Priority Data: 988,427 1 December 1992 (01.12.92) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71)(72) Applicants and Inventors: WÄRRI, Anni, Maija [FI/FI]; Juhaninkuja 2 as. 2, FIN-21420 Lieto (FI). ALANEN-KURKI, Leena, Maria [FI/FI]; Piispankatu 6 E 31, FIN-20500 Turku (FI). AUVINEN, Petri, Olli, Viljami [FI/DE]; Kirschgartenstrasse 5, Rohrbach, D-69126 Heidelberg (DE). JAAKKOLA, Panu, Mikko [FI/FI]; Kellonsoittajankatu 13 B 20, FIN-20500 Turku (FI). JALKANEN, Markku, Tapani [FI/FI]; Rauvolantie, FIN-20760 Piispanristi (FI). LEPPÄ, Sirpa, Marianne [FI/FI]; Valkintie 14 as 6, FIN-20660 Littoinen (FI). MALLI, Markku, Sakari [FI/FI]; Inkereentie 176, FIN-24280 Salo (FI). VIHINEN, Tapani, Artero [FI/FI]; Kaskenkatu 11 C 54, FIN-20700 Turku (FI).			
(74) Agent: ORION CORPORATION; Orion-Farmos Pharmaceuticals, Patent Department, P.O. Box 65, FIN-02101 Espoo (FI).			
(54) Title: SYNDECAN STIMULATION OF CELLULAR DIFFERENTIATION			
(57) Abstract Methods are provided for altering levels of syndecan within a cell. The methods include enhancing syndecan expression via administration of growth factors, preventing suppression of syndecan expression via administration of anti-steroid agents, and altering syndecan biochemistry within the cell. The methods are used to induce or maintain cellular differentiation, and to decrease the growth of malignant cells. Application of the methods to the treatment of patients, including humans, is provided.			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LV	Latvia	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

SYNDECAN STIMULATION OF CELLULAR DIFFERENTIATION

FIELD OF THE INVENTION

This invention is in the field of cancer biology and therapy. Specifically, the invention is to a method for altering the differentiated state of a cell by altering syndecan expression. The method allows for the normalization of the growth rate and differentiation state of malignant cells, such method being based on the stimulation of syndecan expression in malignant cancer cells. Re-expression of syndecan in such malignant cells promotes their normal differentiated phenotype and prevents their tumor formation. This method may also be applied to normal cells to increase their differentiation, and therefore support the maintenance of cells, e.g. keratin production to prevent baldness.

BACKGROUND OF THE INVENTION

It is becoming more evident that cell surface proteoglycans play an important role in the regulation of cell behavior (Ruoslahti *et al.*, *Cell* 64:867-869 (1991)). Through their covalently bound glycosaminoglycan side chains, such proteoglycans can bind various extracellular effector molecules (Jalkanen, *et al.*, in *Receptors for Extracellular Matrix*, J. MacDonald & R. Mecham, Editors, Academic Press, San Diego, pp. 1-37 (1991)). One central challenge in proteoglycan biology is the need to understand what directive a cell receives by binding different effector molecules via the cell surface proteoglycans. It is further imperative to investigate what kind of intracellular response such binding activates, thereby leading to altered behavior of the cell. The way to approach these questions is to create biological models which are dependent on the expression of any given proteoglycans.

Syndecan is the best characterized cell surface proteoglycan (Saunders *et al.*, *J. Cell Biol.* 108:1547-1556 (1989); Mali *et al.*, *J. Biol. Chem.* 265:6884-6889 (1990)). It was originally isolated from mouse mammary epithelial (NMuMG) cells as a hybrid proteoglycan containing both heparin sulfate and chondroitin sulfate glycosaminoglycan side chains (Rapraeger *et al.*, *J. Biol. Chem.* 260:11046-11052 (1985)). Recent studies have revealed its expression, not only on epithelial cells but also on differentiating fibroblasts of developing tooth (Thesleff *et al.*, *Dev. Biol.* 129:565-572 (1988); Vainio *et al.*, *J. Cell Biol.*

108:1945-1964 (1989)), on endothelial cells of sprouting capillaries (Elenius *et al.*, *J. Cell Biol.* 114:585-596 (1991)) and on the surface of lymphocyte subpopulations (Sanderson *et al.*, *Cell Regul.* 1:27-35 (1989)) intimating that its function can vary on the surfaces of different cells. Syndecan belongs to a family of proteoglycans with conserved plasma membrane and cytoplasmic domains but with dissimilar ectodomains (Mali *et al.*, *J. Biol. Chem.* 265:6884-6889 (1990)). The conserved structure of syndecan suggests that it could participate in signal transduction through the plasma membrane.

Syndecan binds several extracellular effector molecules but this binding is selective. For example, syndecan binds interstitial collagens and fibronectin but does not bind to vitronectin or laminin (Koda *et al.*, *J. Biol. Chem.* 260:8156-8162 (1985)); Saunders *et al.*, *J. Cell Biol.* 106:423-430 (1988); Elenius *et al.*, *J. Biol. Chem.* 265:17837-17843 (1990)). Moreover, syndecan isolated from tooth mesenchyme has revealed selective binding to tenascin not observed for syndecan from NMuMG cells (Salmivirta *et al.*, *J. Biol. Chem.* 266:7733-7739 (1991)). This suggests variation in syndecan glycosylation that results in the selective binding properties for syndecan. Polymorphism of syndecan glycosylation has also been observed between simple and stratified epithelia (Sanderson *et al.*, *Proc. Natl. Acad. Sci. USA* 85:9562-9566 (1988)); but whether these changes also reflect altered ligand recognition by syndecan remains unknown. Syndecan also binds growth factors, such as basic fibroblast growth factor (bFGF) (Kiefer *et al.*, *Proc. Natl. Acad. Sci. USA* 87:6985-6989 (1990); Elenius *et al.*, *J. Biol. Chem.* 267:6435-6441 (1992)). Very recently, Yayon and coworkers (Yayon *et al.*, *Cell* 64:841-848 (1991)) and Rapraeger and co-workers (Rapraeger *et al.*, *Science* 252:1705-1708 (1991)) have shown that heparin-like molecules are required for the binding of bFGF to its high affinity receptor, indicating that syndecan-like molecules can also modulate the growth factor response. The fact that cell surface proteoglycans can bind both growth factors and matrix components could theoretically imply a role in regulating, both temporally (timing of expression) and spatially (precise localization), growth promotion by immobilizing these effector molecules to the vicinity of cell-matrix interactions. This is supported by the intriguing pattern of syndecan expression in the development that follows morphogenetic rather than histological patterns (Thesleff *et al.*, *Dev. Biol.* 129:565-572 (1988); Vainio *et al.*, *J. Cell Biol.* 108:1945-1954 (1989) and Vainio *et al.*, *Dev. Biol.* 134:382-391 (1989)), and moreover, that syndecan expression is localized to sites of active proliferation (Elenius *et al.*, *J. Cell Biol.* 114:585-596 (1991) and Vainio *et al.*, *Dev. Biol.* 147:322-333 (1991)).

In simple epithelium, syndecan is polarized to baso-lateral surfaces where it co-localizes with actin rich cytofilaments (Rapraeger *et al.*, *J. Cell Biol.* 103:3683-2696 (1986)). Upon rounding, syndecan is shed from the cell surface by proteolytic cleavage of the core protein at the cell surface, a process which separates the matrix binding ectodomain from the membrane domain (Jalkanen *et al.*, *J. Cell Biol.* 105:3087-3096 (1987)). By this way, syndecan has been proposed to be involved in the maintenance of epithelial morphology. Mouse mammary tumor cells (S115), when steroid-induced to modulate their morphology from an epithelial to a more fibroblastic or fusiform phenotype, lose syndecan expression (Leppä *et al.*, *Cell Regul.* 2:1-11 (1991)), as to several other cell types *in vivo* when they transform (Inki *et al.*, *Am. J. Pathol.* 139:1333-1340 (1991); Inki *et al.*, *Lab. Invest.* 66:314-323 (1992)), suggesting a general loss of syndecan expression during malignant transformation.

SUMMARY OF THE INVENTION

It is therefore an object of the subject invention to provide a method of altering the differentiated state of a host cell by altering syndecan expression in such cell.

It is a further object of the invention to provide a method to induce and regulate syndecan expression, especially in cells which exhibit a malignant phenotype, regardless of the origin of transformation.

It is a further object of the invention to provide a treatment for the reduction of tumor growth in a patient in need of such treatment, by administration of a composition to such patient, such composition comprising efficacious amounts of one or more agents that stimulate syndecan synthesis in the tumor cells of such patient.

It is a further object of the invention to provide the DNA sequence and localization of promoter, suppressor and enhancer elements for the syndecan gene.

It is a further object of the invention to provide a method for the enhancement of syndecan expression in a host cell, by enhancing syndecan gene transcription.

It is a further object of the invention to provide a method for the enhancement of syndecan expression in malignant cells, by preventing suppression of syndecan gene transcription.

It is a further object of the invention to provide a biochemical method for the inactivation of suppressors of syndecan gene expression in malignant cells.

It is a further object of the invention to provide a method for the stimulation of cellular differentiation by enhancing syndecan expression in both malignant and normal cells.

It is a further object of the invention to provide a method for the stimulation of cellular proliferation and differentiation, thus tissue regeneration, especially in processes such as wound healing, by enhancing syndecan expression.

Further features, objects and advantages of the present invention will become more fully apparent from a detailed consideration of the following description of the subject invention when taken together with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Figure 1 is a diagram of the assembly of mouse syndecan gene and its promoter region.

Figure 2. Figure 2 is the complete sequence of the mouse syndecan gene [SEQ ID Nos. :1: (DNA) and :2: (protein)] and its proximal promoter. Regulatory sites for the expression of syndecan may also exist on the first intron following the first exon (see Figure 1).

Figure 3. Figure 3 is a diagram of the assembly of mouse syndecan promoter region and the localization of the enhancer and suppressor elements together with restrictions sites for three different enzymes.

Figure 4. Figure 4 is the complete sequence of the mouse syndecan enhancer element [SEQ ID No. :3: (DNA)], located 8-10 kbs upstream from the transcription initiation site as indicated in figure 3.

Figure 5. Figure 5A (panels A-D) is a photographic presentation of reduced growth ability of syndecan-transfected cells in soft agar. Panel A (wild-

type S115 cells) and B (control transfected cells) are pictures of the colonies that are formed in soft agar in the presence of testosterone, a feature typical for hormone-transformed cells. This growth ability was not observed with two independent syndecan-transfected cell clones (panels C and D), demonstrating how syndecan re-expression can overcome the effect of hormone-induced transformation. Figure 5B is a graphical presentation of how syndecan-transfected cells lose their ability to form tumors in nude mice. Wild-type or control transfected cells produce tumors in testosterone-administered nude mice while syndecan transfected cells revealed a very low tendency to produce tumors.

Figure 6 is a graphical representation of enhanced syndecan expression in 3T3 cells by simultaneously administered basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF- β). This is an example of how syndecan expression can be enhanced as a result of growth factor action in normal cells during the differentiation process.

Figure 7 is a graphical representation of enhanced syndecan expression by MCF-7 cells exposed to the anti-estrogen toremifene. When exposed to estrogen, syndecan expression in MCF-7 cells was reduced and the cells transformed. Subsequent treatment with the anti-estrogen (toremifene) restored syndecan expression to levels close to that found in cells not exposed to estrogen and aided the cells in maintaining their normal growth behavior.

Figure 8 is a graphical presentation of how the suppressor element (see figure 3) is active in S115 cells treated with testosterone. Indicated stretches of promoter sequences were transfected in hormone-treated S115 cells and analysed for their transcription activity as described in Example VI. A dramatic drop was observed with suppressor construct as indicated in Figure 3, and it was more obvious in transformed S115 (a) cells than in 3T3 cells (b).

Figure 9 is a graphical presentation of how the enhancer element is active in growth hormone-treated 3T3 cells. Various stretches of promoter were transfected in 3T3 cells and analysed for their transcription activities. Fragment pXb6, which is the same as illustrated in Figure 3 as an enhancer, revealed more than ten fold stimulation in 3T3 cells exposed to growth factors bFGF and TGF β compared to non-treated cells.

DEFINITIONS

In order to provide a clearer and more consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

"Enhancement" or "Stimulation" of Syndecan expression. By "enhancement" or "stimulation" of syndecan expression" is meant an effect of increasing the synthesis of syndecan, either by the induction or de-suppression (de-repression) of syndecan gene transcription and/or translation.

Cell growth. By "cell growth" is meant cell replication, both controlled and uncontrolled.

Malignant. By "malignant" is meant uncontrolled cell growth.

More Differentiated Phenotype. In stating that a cell has a "more differentiated phenotype" is meant that the cell possesses a phenotype usually possessed by a certain cell type more differentiated than the cell, which the cell was deficient in prior to enhancement of syndecan expression according to the invention. This phenotype may be defined by one or more phenotypic characteristics. For example, an epithelial cell is a more differentiated phenotype of a mesenchymal-like shape; therefore, the ability of the method of the invention to maintain cells in an epithelial cell morphology rather than a mesenchymal-like shape is a more differentiated phenotype within the meaning of the definition. Continuous syndecan expression is necessary for the maintenance of terminal differentiation of epithelial cells.

Syndecan expression is also linked to the normal differentiation of mesenchymal cells. However, only a transient increase in syndecan expression is needed for normal differentiation in mesenchymal cells. Therefore, contrary to epithelial cells, expression of syndecan is not needed for maintenance of terminal differentiation in mesenchymal cell. To induce differentiation of a suitable mesenchymal precursor cell population (such as a "condensing mesenchymal" cell population) to a fully differentiated mesenchymal cell, there is needed only a transient expression of syndecan expression. Therefore, a terminally differentiated mesenchymal cell is a "more differentiated phenotype" than a condensing mesenchymal cell.

Other useful phenotypes that are present in syndecan-deficient cells and not in cells expressing sufficient syndecan include fusiform shapes with long filopodial extensions with extensive under-and overlapping of these processes (so that the cells appear to have a defect in cell adhesion).

In another example, syndecan-deficient NMuMG cells continue to secrete milk fat globule antigen (and thus appear mammary-like) and continue to express cytokeratins (thus appear epithelial-like). However, their actin-containing cytoskeleton is disorganized and their expression of beta₁ integrins and E-cadherins at the cell surface is markedly reduced. Upon expression of sufficient syndecan, these phenotypes are corrected so that there is no reduction in cell surface integrins or E-cadherin and the cell has an epithelial morphology. Therefore, the amount of cell surface integrins or E-cadherin are useful markers of syndecan expression and may be used to monitor what amount of a drug is needed for efficacious results according to the method of the invention.

Efficacious Amount. An "efficacious amount" of an agent is an amount of such agent that is sufficient to bring about a desired result, especially upon administration to an animal or human.

Administration. The term "administration" is meant to include introduction of agents that induce syndecan expression into an animal or human by any appropriate means known to the medical art, including, but not limited to, injection, oral, enteral and parenteral (e.g., intravenous) administration.

Pharmaceutically Acceptable Salt. The term "pharmaceutically acceptable salt" is intended to include salts of the syndecan-inducing agents of the invention. Such salts can be formed from pharmaceutically acceptable acids or bases, such as, for example, acids such as sulfuric, hydrochloric, nitric, phosphoric, etc., or bases such as alkali or alkaline earth metal hydroxides, ammonium hydroxides, alkyl ammonium hydroxides, etc.

Pharmaceutically Acceptable Vehicle. The term "pharmaceutically acceptable vehicle" is intended to include solvents, carriers, diluents, and the like, which are utilized as additives to preparations of the syndecan-inducing agents of the invention so as to provide a carrier or adjuvant for the administration of such compounds.

Treatment. The term "treatment" or "treating" is intended to include the administration of compositions comprising efficacious amounts of syndecan-

inducing agents to a subject for purposes which may include prophylaxis, amelioration, prevention or cure of a medical disorder, including tumor growth, hair growth.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Briefly, in its broader aspects the present invention comprehends a method for maintaining a differentiated phenotype in a normal (non-malignant) cell that otherwise would suppress syndecan expression, by maintaining syndecan expression in such cell. The invention also comprehends a method for inducing a more differentiated phenotype in a malignant cell that lacks (or is deficient in) syndecan expression, by stimulating syndecan expression in such a cell. As used herein, if a cell is said to "lack" syndecan expression, it is meant to include cells that are either completely deficient in syndecan protein or produce insufficient syndecan levels to maintain or attain a desired differentiated phenotype.

The methods of the invention will not only prevent the progression (worsening) of a transformation state and tumor growth of cells, but can also be used to maintain differentiated cells in their differentiated state so that they continue to perform differentiated functions characteristic of such cells. Examples of differentiated functions of non-malignant cells include the secretion characteristics of a cell (that is, the secretion of specific proteins and/or other macromolecules) and hair formation by epidermal cells of skin. Thus, according to the invention, administration of agents capable of inducing syndecan expression in epidermal skin cells of the scalp will promote hair growth among bald (or balding) people.

The subject method may be accomplished in a variety of manners including biochemical, chemical or even molecular biological type methods. While the method is applicable to a variety of cancer (both malignant and non-malignant) and normal cells, it is particularly adaptable for treating malignant cells which have become transformed. This includes cells transformed due to hormonal influences of the body or environmental influences, such as chemicals or radiation exposure. Especially, the tumor type is a tumor characterized by loss of syndecan, for example, a glioma, myeloma, carcinoma, sarcoma, lymphoma, or adenoma.

Generally, any cell genetically capable of expressing syndecan can be a cell stimulated to express syndecan by the method of the invention. Syndecan--

is naturally expressed in a wide variety of epithelial cells in mature and embryonic tissues and by various embryonic mesenchymal tissues undergoing inductive interactions with epithelia. In addition, syndecan is naturally expressed on Leydig cells and on developing B-lymphocytes and a subpopulation of plasma cells.

Enhanced syndecan expression may be achieved by administration of compositions containing a biochemically, and/or chemically and/or molecular-biologically active component to an individual. Compositions may be administered orally, intravenously, subcutaneously or locally, or by any other method which will allow cells, normal or malignant, to be exposed to syndecan expression enhancing component.

By a "biochemically" or "chemically" active component is meant a component that alters the endogenous syndecan biochemistry or chemistry of the target cell without altering syndecan gene expression *per se*. For example, such alterations may include altering the half-life of syndecan protein or mRNA, so as to increase levels of syndecan protein in the cell, for example, by altering the external domain of the cell's endogenous syndecan, or the cell surface membrane properties in general, so as to retain higher levels of syndecan on the cell surface; and, altering the syndecan protein active site(s), so as to enhance the efficiency of the syndecan response.

By a "molecular-biologically" active component is meant a component that alters endogenous syndecan gene expression in a manner that allows for an increase in cellular syndecan, such as, for example, by stimulating transcription, preventing (or reducing) suppression of transcription, de-repression transcription, and generally increasing levels of mRNA and/or translation efficiency.

It is known that cellular transformation involves activation of some cell growth stimulating genes (like oncogenes) and inactivation of some other genes, which work to suppress cell growth. It has recently been shown that loss of syndecan expression is observed upon transformation of cells, and that this suppression is due to syndecan gene inactivation (Leppä *et al.*, *Cell Regul.* 2:1-11 (1991); Inki *et al.*, *Am. J. Pathol.* 139:1333-1340 (1991); Inki *et al.*, *Lab. Invest.* 66:314-323 (1992)). This was demonstrated in several biological models of various known carcinogenic systems (oncogenes, chemical carcinogens, UV-light, hormone-exposure, etc.). Therefore, syndecan gene suppression is implicated in the development of cellular transformation.

Further, according to the invention, all the manipulations of such cells which can induce syndecan expression in malignant cells, also induce these cells to obtain a more differentiated phenotype, and thus, subsequently reduce their potential tumorigenic behavior and metastasis.

In a preferred embodiment, the cell in which syndecan expression is stimulated is a cell that is steroid-responsive. Examples of such steroid-responsive cells include breast cells, endometrium cells and prostate cells, especially in the malignant state. In a highly preferred embodiment, the cell is responsive to estrogen and/or androgen.

Examples of other cell types that will respond to the treatment of the invention include malignant and non-malignant mesenchymal cells.

The regulatory elements of a given gene are commonly located upstream from (5' to) the transcription initiation site. Syndecan, however, has a very peculiar gene structure, in which the first and second exons are separated by a very large intron (Figure 1). This could mean that, in addition to the base sequences upstream from the transcription site, syndecan expression may also be susceptible to regulation by base sequences located between first and second exons (Figure 2), that is, in the first intron.

It has now surprisingly been found that the syndecan gene has a strong enhancer element located 8-10 kb upstream from the transcription initiation site. The sequence of this enhancer element has been identified and is given in Figure 4 [SEQ ID. No. 3].

Manipulation of the upstream region of the syndecan gene can block its inactivation during malignant transformation. For example, replacement of the region in front of first exon of the syndecan gene with the glucocorticoid-inducible elements of mouse mammary tumor virus (MMTV) not only blocks syndecan suppression during malignant transformation, but also inhibits the ability or potential of cells to transform and become tumorigenic (Figure 3). These findings suggest a very important role for syndecan in the maintenance of normal epithelial morphology (Leppä *et al.*, *Proc. Natl. Acad. Sci. USA* 89:932-936 (1992)).

Cells destined to differentiate during organ formation or tissue regeneration also exhibit enhanced syndecan expression (Vainio *et al.*, *Dev. Biol.* 147:322-333 (1991); Elenius *et al.*, *J. Cell Biol.* 114:585-595 (1991)). The component(s) responsible for the regulation of syndecan expression (either

directly or indirectly) have not yet been identified. Growth factors are candidates for this role since they are known to be involved in the regulation of early development and cellular differentiation (Heath *et al.*, *Curr. Opin. Cell Biol.* 3:935-938 (1991)). Involvement of growth factors is also supported indirectly by the fact that the expression of two embryonally important growth factors (TGF- β and FGF) has been shown to coincide with syndecan within developing tooth (Vaahtokari *et al.*, *Development* 113:985-994 (1991); Wilkinson *et al.*, *Development* 105:131-136 (1989)).

Based on these findings the possible effect of growth factors on the expression of syndecan has been tested. It was shown that both bFGF and TGF- β alone, but especially if administered in combination, enhance syndecan expression by 3T3 cells (Figure 4). This stimulation is close to the levels observed in syndecan-expressing epithelial cells (Elenius *et al.*, *J. Biol. Chem.* 267:6435-6441 (1992)) prior to their malignization (Leppä *et al.*, *Proc. Natl. Acad. Sci. USA* 89:932-936 (1992)). These findings suggest that growth factors, and their derived fragments and domains may prove to be valuable for the development of an active tool for the regulation of syndecan expression.

Preferably, for treatment of humans and animals, a drug is administered that results in the enhancement of syndecan expression to levels sufficient to facilitate cellular differentiation in the degenerative stages of tissues. Such drugs are herein termed "syndecan-inducing agents." Syndecan-inducing agents include the growth factors and their derivatives that retain growth-factor activity. Examples of such growth factors include bFGF, and TGF- β , whether administered separately or together.

Even more preferred is a syndecan-inducing agent that has good tissue and cell penetration so that it could directly interfere with suppressor(s) of syndecan expression within cell nuclei. Such a syndecan-inducing agent is the known antitumor drug toremifene. When toremifene, known to have good plasma membrane penetration, is administered to the hormone-transformed epithelial cells with reduced syndecan expression, the cells reverse their lowered syndecan expression, and induce syndecan levels to those close to the level observed with normal, non-transformed cells (Figure 5). This demonstrates that syndecan-inducing agents useful in the methods of the invention are known and available and that such agents can specifically prevent cellular malignization by blocking suppression of syndecan expression. Another useful drug in this regard is tamoxifen.

Such syndecan-inducing agents may be administered using currently available preparations, or in any pharmaceutically acceptable vehicle. The route of administration may be any route that delivers efficacious levels of the drug to the desired active site, for example, by injection.

For parenteral administration, preparations containing one or more syndecan-inducing agents may be provided to the patient in need of such treatment in combination with pharmaceutically acceptable sterile aqueous or non-aqueous solvents, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil, fish oil, and injectable organic esters. Aqueous carriers include water, water-alcohol solutions, emulsions or suspensions, including saline and buffered medical parenteral vehicles including sodium chloride solution, Ringer's dextrose solution, dextrose plus sodium chloride solution, Ringer's solution containing lactose, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based upon Ringer's dextrose and the like.

The syndecan-inducing agent of the invention can be employed in dosage forms such as tablets, capsules, powder packets, or liquid solutions for oral administration if the biological activity of the syndecan-inducing agent is not destroyed by the digestive process and if the characteristics of the compound allow it to be absorbed across the intestinal tissue.

The syndecan-inducing agents may also be administered by means of pumps, or in sustained-release form. The syndecan-inducing agents used in the method of invention may also be delivered to specific organs in high concentration by means of suitably inserted catheters, or by providing such molecules as a part of a chimeric molecule (or complex) which is designed to target specific organs.

Administration in a sustained-release form is more convenient for the patient when repeated injections for prolonged periods of time are indicated.

The composition containing the syndecan-inducing agent can be manufactured in a manner which is in itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, lyophilizing or similar processes. The compositions of the present invention that provide the syndecan-inducing agent, in and of themselves, find utility in their ability to slow or prevent tumor growth or tumor reappearance. The syndecan-inducing

compositions of the invention utilize the body's own mechanisms for promoting differentiation of specific cell types to its maximum potential.

In intravenous dosage form, the compositions of the present invention have a sufficiently rapid onset of action to be useful in the acute management of tumor growth.

Additionally, a low potency version is useful in the management of disorders wherein a tumor has been effectively treated and the patient appears to be in remission, but it is desired to maintain sufficient levels of syndecan-inducing agents in the patient so as to assist the body in preventing a recurrence of the tumor.

Typical doses of toremifene or tamoxifen, and other such syndecan-inducing agents useful in the methods of the invention for treatment of humans or other animals are 20-600 mg daily, and preferably 20-60 mg daily.

The examples below are for illustrative purposes only and are not deemed to limit the scope of the invention.

EXAMPLE I

Reversal of hormone-induced transformation by exogenous syndecan expression.

As previously described (Leppä *et al.*, *Cell Regulation* 2:1-11 (1991)), S115 mouse mammary tumor cells were routinely cultured in DMEM. For experimental studies involving hormone treatment, inactivated fetal calf serum (i-FCS) was replaced with 4% dextran charcoal-treated fetal calf serum (DCC-FCS), which eliminates endogenous steroids from serum), and used either with or without testosterone (10 nM) and with or without dexamethasone (10 nM or 1 μ M). Cells were plated at a density of 10,000 cells/cm² and the medium was replenished every 3 days.

Plasmid pUC19-hsynpr7 containing human syndecan cDNA (Mali *et al.*, *J. Biol. Chem.* 265:6884-6889 (1990)) was digested with *NaeI* restriction endonuclease, and the derived 336 bp long-fragment was separated in and eluted from low melting agarose gel. Plasmid pUC19-hsyn4 (Mali *et al.*, *J. Biol. Chem.* 265:6884-6889 (1990)) was digested with *NaeI* and *HindIII* (polylinker site), and the plasmid-containing fragment starting from base 487 was isolated. The *NaeI* fragment from hsynpr7 was ligated to the pUC-hsyn *NaeI/HindIII*

digested vector. The orientation of insert was verified by restriction enzyme analysis and sequencing. The derived plasmid, containing the full coding region of human syndecan core protein, was named pUC19-hsynfull. This plasmid was further digested with *Bam*HI and *Sph*I (polylinker site). A fragment containing syndecan coding region bases 150-1461 was isolated and blunt-ended, using Klenow and T4 DNA polymerase. Finally, this fragment was ligated to *Sa*I-linearized and blunt-ended pMAMneo vector (Clontech; Palo Alto, CA), resulting in a chimeric gene containing RSV-MMTV-LTR promoter connected to human syndecan coding region and SV-40 polyadenylation signal. The orientation was confirmed by restriction enzyme digestions. The plasmid was named pMAMneo-hsyn.

For control transfections, a 642 bp long-*Hind*III/*Pvu*II fragment of human growth hormone gene (consisting of exons 4 and 5; Bornstein *et al.*, *J. Biol. Chem.* 263:1603-1606 (1988)) was blunt-ended and cloned into the same pMAMneo vector, as described above. This control construct was named pMAMneo-hGH.

All plasmids were isolated using the CsCl density gradient method. Before transfections, plasmids were linearized with *Mlu*I, chloroform/phenol extracted and ethanol precipitated.

Transfections were performed using Lipofectin™ (BRL), according to manufacturer's instructions. After selection for two weeks (G418; 750 µg/ml, Sigma), surviving clones were isolated from growth plates using cloning cylinders. The expression of human syndecan or growth hormone (consisting of exons 4 and 5) mRNAs was then confirmed by RNA isolation and Northern blot analysis. Clones expressing high levels of transfected genes were selected for further studies and characterizations. These stock cells were routinely cultured in the presence of G418 (300 µg/ml).

For the measurement of exogenous syndecan expression total RNA was isolated from wild-type S115 cells and cells transfected with human syndecan or growth hormone genes. RNA was extracted using 4M guanidine isothiocyanate and CsCl pelleting, as earlier described by Chirgwin *et al.*, *Biochemistry* 18:5294-5299 (1979)). RNA from normal mouse mammary NMuMG and normal human mammary HBL-100 cells was used for comparison. RNA aliquots of 15 µg were separated in 1% formaldehyde agarose-gel electrophoresis and transferred to GeneScreen Plus™ hybridization membrane (New England Nuclear). Blots were hybridized with multiprime (Amersham)

labeled inserts of either mouse (PM-4) (Saunders *et al.*, *J. Cell Biol.* 108:1547-1556 (1989)) or human syndecan (pUC19-hsyn4 *Bam*HI 1.1 kb fragment) (Mali *et al.*, *J. Biol. Chem.* 265:6884-6889 (1990)), or with human growth hormone exons 4 and 5 (hGH) (Leppä *et al.*, *Proc. Natl. Acad. Sci. USA* 89:932-936 (1992)) cDNAs, using the high stringency conditions suggested by the manufacturer of the membrane (New England Nuclear). All techniques based on modern molecular biology are fully explained in the literature such as in the laboratory manual entitled *Current Protocols in Molecular Biology*.

Anchorage independent cell growth was measured in a soft agar colony assay. The six well-plates were first covered with an agar layer consisting of 2 ml DMEM, 0.5% agar and 4% DCC-FCS. The middle layer contained 10^4 cells in 0.5 ml DMEM supplemented with 0.33% agar and 4% DCC-FCS, with or without 10 nM testosterone. The uppermost layer, consisting of medium (2 ml), was added to prevent drying of the agarose gels. The plates were incubated at 37°C in 5% CO₂ for 12 days after which cultures were evaluated and photographed.

Tumorigenicity of S115 wild type cells, one hGH transfected control clone and two clones expressing human syndecan-1 was measured in nude mice. For this cells were cultured in DMEM containing 5% FCS and 10 nM testosterone. After four days in culture, cells were harvested with trypsin, washed, and 10^7 cells suspended in 0.2 ml of DMEM were injected subcutaneously into back of athymic male nude mice (balb-C). Silastic testosterone capsule, which is known to increase the growth rate of S115 cells (King *et al.*, *J. Steroid. Biochem.* 7:869-873 (1976)) was simultaneously implanted. Nude mice were examined regularly for tumor development and the size of the palpable tumors measured at intervals.

EXAMPLE II

Growth factors enhance syndecan expression.

NMuMG mouse mammary epithelial cells and 3T3 (NIH) mouse fibroblasts were routinely cultured in bicarbonate-buffered Dulbecco's modified Eagle's medium (DMEM; GIBCO) containing 10% FCS (GIBCO) and antibiotics, as previously described (Elenius *et al.*, *J. Biol. Chem.* 265:17837-17843 (1990)). For experiments, cells were plated at equal density on culture dishes (Nunc) and grown to 60 - 70% confluency. Twenty-four hours before supplementing growth factor(s) to the medium, fresh medium containing 2%

CMS-FCS (Vogel *et al.*, *Proc. Natl. Acad. Sci. USA* 75:2810-2814 (1978)) was replaced. Equally treated cultures without growth factor addition served as negative controls. Porcine TGF β 1 (R&D), recombinant human bFGF (Boehringer) and murine EGF (Sigma) were used in final concentrations of 2.5 ng/ml (100 pM), 10 ng/ml (570 pM) and 1.2 ng/ml (200 pM) respectively, in all experiments. For quantitation and isolation of cell surface syndecan, media were discarded at time points indicated in the text and the cell layers were washed twice with ice cold phosphate buffered saline (PBS). Cells were scraped with a rubber policeman into ice cold PBS supplemented with 0.5 mM EDTA and centrifuged. After subsequent washes by resuspension and centrifugation the cell numbers were measured by counting the nuclei with a Coulter Counter (Coulter Electronics).

For quantitation of syndecan intercalated into the cell membrane, syndecan ectodomain was released by incubating washed cells in 20 μ g/ml bovine pancreatic trypsin (Type III; Sigma) in PBS for 10 min on ice bath. After incubation the cells were centrifuged, leaving the ectodomain in the supernatant (Rapraeger *et al.*, *J. Biol. Chem.* 260:11046-11052 (1985)). Sample volumes equal to 400,000 or 200,000 cells for 3T3 or NMuMG cells, respectively, were loaded on cationic nylon membrane (Zeta-Probe; BioRad) in a minifold-slot apparatus (Schleicher and Schuell), as previously described (Jalkanen *et al.*, *J. Cell Biol.* 105:3087-3096 (1987)). Nonspecific binding was blocked by incubating the membrane for one hour at room temperature in PBS containing 10% FCS. Syndecan attached to the membrane was detected with a monoclonal antibody against mouse syndecan core protein (mAB 281-2) (Jalkanen *et al.*, *J. Cell Biol.* 101:976-984 (1985)) that was radiolabeled by chloramine-T oxidation method (Stähli *et al.*, *Meth. Enzymol.* 92:242-253 (1983)). The membrane was incubated overnight at 4°C with 125 I-labeled 281-2 in PBS + 10% FCS (10,000 CPM/ml). After five washes with PBS the bound antibody was visualized by autoradiography.

The accumulation of syndecan ectodomain into the medium was estimated by taking samples corresponding to 1/50 (3T3 cells) or 1/100 (NMuMG cells) of the total volume of the remaining medium at selected time points. The samples were analyzed by loading them to nylon membrane as described above. The autoradiography signal was quantitated with a GelScan XL ultrascan densitometer (LKB) using GelScan XL 2400 software (LKB).

For syndecan purification, cells were radiolabeled for 24 hours in low sulfate DMEM (MgCl $_2$ substituted for MgSO $_4$; 2% CMS-FCS) with 100 μ Ci/ml

$^{35}\text{SO}_4$ (New England Nuclear) in the presence or absence of growth factor(s). Cell surface trypsin-releasable material was collected, as described above, and after dialysis against Tris-buffered saline (TBS), the sample was loaded onto a 281-2-Sepharose CL-4B immunoaffinity column (Jalkanen *et al.*, *J. Cell Biol.* 105:3087-3096 (1987)). Bound material was eluted with 50 mM triethylamine (TEA) (pH 11.5) and the amount of radioactive PG in each fraction was analyzed using cetylpyridiumchloride-impregnated Whatman 3MM filter discs (Rapraeger *et al.*, *J. Biol. Chem.* 260:11046-11052 (1985)). For interaction experiments, fractions containing most of the labeled PG were pooled and dialyzed against PBS.

To obtain unlabeled syndecan ectodomain for interaction assays (see below) the same procedure was used except that no radioactive sulfate was added to the culture medium and the syndecan containing fractions eluted from the immunoaffinity column were detected by immuno-dot assay using mAB 281-2. The estimation of the molar concentration of syndecan was based on the use of previously determined syndecan concentration by total amino acid analysis (Jalkanen *et al.*, *J. Cell Biol.* 106:953-962 (1988)).

SDS-PAGE and Western Blot - For western blot experiments cells were cultured 24 hours with or without growth factor(s). Syndecan ectodomain containing material released from the cell surface by trypsin treatment was fractionated on SDS-PAGE gradient (2 -15%) gel (O'Farrel, *J. Biol. Chem.* 250:4007-4021 (1975)). After electrophoresis, samples were transferred onto Zeta-Probe membrane using electroblotting 2005 Transphor apparatus (LKB). The syndecan antigen on the filter was detected with radiolodinated mAB 281-2 and the filter was washed, as described above for slot blot analysis.

Northern Blot - RNA was isolated from 3T3 and NMuMG cells using 4 M guanidine isothiocyanate and CsCl density centrifugation (Chirgwin *et al.*, *Biochemistry* 18:5294-5299 (1979)). RNA samples were size-separated on 1% agarose formaldehyde gel, transferred to GeneScreen PlusTM membrane (New England Nuclear) and hybridized with multi-prime (Amersham) labeled partial cDNA clone for mouse syndecan (PM-4) (Saunders *et al.*, *J. Cell Biol.* 108:1547-1556 (1989)). After hybridization the membrane was washed in 2 x SSC and 1.0% SDS at 65°C (high stringency conditions). For rehybridization with glyceraldehyde-3-phosphate-dehydrogenase (GAPDH; Fort *et al.*, *Nucleic Acid Res.* 13:1431-1442 (1985)) the bound PM-4 probe was removed as recommended by the manufacturer of the filter (NEN).

EXAMPLE III

Induction of syndecan mRNA expression in the human breast cancer cells (MCF-7) growth-inhibited with toremifene.

The steroid-responsive human breast cancer cell line MCF-7 was used to study the expression of human syndecan under different growth conditions regulated by estrogen and antiestrogen. For the experiment cells were plated at a density of 1.2×10^6 cells/100 mm ϕ plastic culture dishes and grown as monolayer cultures in 10 ml per dish of phenol red-free DMEM medium with 5% dextran/charcoal stripped fetal calf serum (DS-FCS), 2 mM L-glutamine and 3 μ g/ml Insulin. For hormone-treatment 1 nM 17 β -O-estradiol (E₂), alone or with 1-6.25 μ M toremifene, dissolved 70% in ethanol, were added to the culture medium on the day following plating. The cells were cultured for 6 days, and the media were changed every second day. For RNA extraction the cells were washed *in situ* with PBS and scraped from the plates in 4 M guanidine isothiocyanate.

EXAMPLE IV

Treatment of Steroid-Responsive Tumors in Patients.

Patients diagnosed as having a steroid-responsive tumor selected from a breast tumor, an endometrium tumor, a prostate gland tumor or a mesenchymal tissue tumor are administered a composition that contains efficacious amounts of the anti-steroid agent toremifene or tamoxifen, or efficacious amounts of the growth factor bFGF, TGF- β or bFGF together with TGF- β , in amounts ranging from 20-600 mg per day, depending upon the extent of the tumor, the patient's age, the patient's sex, and other treatments such as are taken into consideration in designing such chemotherapeutic protocols. The syndecan-inducing agent is administered for a period of time sufficient to induce syndecan in the tumor cells, such that the tumor cells now take upon a more differentiated phenotype and such that the growth of the tumor is arrested or significantly slowed by the treatment.

EXAMPLE V

Stimulation of Hair Growth in Epidermal Skin Cells.

Patients diagnosed as being in need of increased hair growth in the scalp region are administered a composition that contains efficacious amounts

of the anti-steroid agent toremifene or tamoxifen, or efficacious amounts of the growth factor bFGF, TGF- β or bFGF together with TGF- β , in amounts ranging from 20-600 mg per day, depending upon the extent of the needed hair growth, the patient's age, the patient's sex, and other treatments such as are taken into consideration in designing such protocols. The syndecan-inducing agent is administered for a period of time sufficient to induce syndecan in the epidermal cells, such that hair growth is significantly increased by the treatment.

EXAMPLE VI

Dermination of Mouse Syndecan Promoter and Enhancer Activities

The mouse syndecan gene has been cloned and characterized up to -10 kbs upstream from the transcription start site. To determine the specific activities of different proximal promoter regions (up to -2 kbs from the start site) and enhancer regions (from -2 to -10 kbs) we have made plasmid constructs where these regions were cloned into pCAT basic or pCAT promoter vectors, containing the CAT reporter gene. The reporter CAT gene produces chloramphenicol acetyltransferase enzyme, which transfers the n-butyryl moiety of n-butyryl CoA to chloramphenicol. The n-butyryl chloramphenicol can be separated from native chloramphenicol by xylene.

For the further characterization of the proximal syndecan promoter a series of retriCTION enzyme treatments was made on the upstream region (Hind III, Hind II, Bgl II, Stu I, Dra I, Cla I, BamHI and Pst I - Xho I) and the obtained fragments were cloned into the pCAT basic vector. For enhancer areas, three Xba I fragments were cloned into a pCAT promoter vector, where the SV 40 promoter was displaced by the Bgl II - Xho I fragment from the syndecan promoter.

The plasmid constructs were transiently transfected into eukaryotic cells by calcium phosphate precipitation simultaneously with a β -Galactosidase expressing vector to determine the transfection efficiency. After a four hour incubation cells were treated with 15% glycerol and grown for approximately 48 h in cell culture medium. Cells were then scraped from dishes in TEN-buffer and the cytoplasmic extract was obtained by repeated freezing and thawing. β -Galactosidase acitivity was obtained in hte cytoplasmic extreact by adding 0.1 M sodium phosphate, 45 mM mercaptoethanol and 0.2 mg ONPG. This was incubated from 2 hours to overnight and the colour reaction was measured spectrofotometrically at 420 nm.

The CAT activity was determined by adding 0.25 M Tris buffer, 25 ng n-butyryl CoA and 0.0626 μ Ci of 14 C-chloramphenicol to the cytoplasmic extract. These were incubated overnight, backextracted with xylene and radioactivity was measured by scintillation counting. The CAT activity was corrected for transfection efficiency by β -galactosidase activity.

The cells used for proximal promoter constructs were 3T3 NIH, S115 (either hormone-treated or not) and nMuMG cells. For enhancer constructs we used 3T3 NIH cells grown in 2% CMS medium and to test the effect of growth factors in 2% CMS medium with 10 ng/ml FGF-2 and 2ng/ml TGF β -1.

All references cited herein are fully incorporated herein by reference. Having now fully described the invention, it will be understood by those with skill in the art that the scope may be performed within a wide and equivalent range of conditions, parameters and the like, without affecting the spirit or scope of the invention or any embodiment thereof.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Alanen-Kurki, Leena
 - (B) STREET: Piispankatu 6 E 31
 - (C) CITY: TURKU
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-20500
-
- (A) NAME: Auvinen, Petri
 - (B) STREET: Kirschgartenstrasse 5
 - (C) CITY: HEIDELBERG
 - (E) COUNTRY: GERMANY
 - (F) POSTAL CODE (ZIP): D-69126
-
- (A) NAME: Jaakkola, Panu
 - (B) STREET: Kellonsoittajankatu 13 B 20
 - (C) CITY: TURKU
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-20500
-
- (A) NAME: Jalkanen, Markku
 - (B) STREET: Rauvolantie
 - (C) CITY: PIISPANRISTI
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-20760
-
- (A) NAME: Leppa, Sirpa
 - (B) STREET: Valkintie 14 as 6
 - (C) CITY: LITTOINEN
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-20660
-
- (A) NAME: Mali, Markku
 - (B) STREET: Inkereentie 176
 - (C) CITY: SALO
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-24280
-
- (A) NAME: Vihinen, Tapani
 - (B) STREET: Kaskenkatu 11 C 54
 - (C) CITY: TURKU
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-20700
-
- (A) NAME: Warri, Anni
 - (B) STREET: Juhaninkuja 2 as 2
 - (C) CITY: LIETO
 - (E) COUNTRY: FINLAND
 - (F) POSTAL CODE (ZIP): FIN-21420

(ii) TITLE OF INVENTION: SYNDECAN STIMULATION OF CELLULAR
DIFFERENTIATION

(iii) NUMBER OF SEQUENCES: 3

- (iv) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
- (v) CURRENT APPLICATION DATA:
 APPLICATION NUMBER: WO TO BE ASSIGNED
- (vi) PRIOR APPLICATION DATA:
 (A) APPLICATION NUMBER: US 07/988427
 (B) FILING DATE: 01-DEC-1992

(2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26700 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: join(4378..4443, 22026..22106, 23001..23483, 23905..24039, 24251..24418)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TCTAGATATT CAAACTCACC AGATGGAGTG ATGTCCACCC CTATTGGTGG GAGTGACTAG	60
TCTTTCCTCT GTCTTCTGAC TCAGATGCTT AGCTAGCTCT TTAGGACCCA CCCTCACACC	120
TGCAAATAAT ACTTTATTTG CTCTCTTAGT ACCTTTAACC CAGTGGAGTT GACATGAGAA	180
ATTA ACTACC ATAATTTATA ATATTTTCATT TCATAAATGA AAAGTAAAAT AAATTAAAAA	240
ATAGAAAGGT TTGAGCATGA TGGCCCAGTG GTAAAGGCCA GTGGCTCCAA CGCAAGTCCT	300
GACAAATGGT AACGGGCCTG TTCTTCAGGC TTGAGGGAAG TTTATTGATT GAGGCTAAAA	360
GCAACCCAAA GGCTCCACTT GCCTAGTGTG AAGCCCTGGA TGTGCTCTCC CACACTGCAT	420
GTCCACCTGT GGTGTCAGCA CCTGGGAAGC TGAGGATGAT GGGGAGTCCA AGGTCATTAG	480
CTACATAGTA TAGGCTAGCT GGGGTACATG GGTCACAAAA AAGAAAAAAA AATAAGCACA	540
TTGTAATCCC AGCACTTGAC AGACCAATGG GGGGGGGATT GCTGTGAGTT TAAGACAGCC	600

TGGCCTACAA	AGAAAAACCC	TACCCAAACC	CAAGAAAAAT	GAAACCAGTA	ATATAAATAG	660
CTATTTTCAT	TTTAAATGCT	CTAAAGACAC	AGCGTTAACA	CAAAAGCTCT	CGTCTGTGGT	720
TCCTATTCCC	TCCTTCTCCC	CCAGGTCTTC	TTTAATGTAT	ACTTTTTGTT	TGCTTATTTG	780
CTTGTTTTGG	ATTTTGGCTT	TTAAAGACAG	GGTCTCACTA	TGTAGCTCCA	ACTATTTGGG	840
AACTCACTAT	GTAGACCAGG	CTAGCCAGGG	ACTTATAGAG	ATCTACCTAC	CACTGCCTCC	900
CAAGTGCTGA	GACTAAAGGC	ATGTGACACT	TTGCTTGGTT	ATTACAAACA	TTTTAAAAGA	960
ACATTTTGAA	CATTAATAGA	TGTATGTATA	TATATCACTC	TATGTAGTAT	ATATGTTAGA	1020
CATTTTTCAC	TTGAGATACA	TATTTACTCT	CAAAATAAGT	TTTTTGTTTT	TTTTTCTTCT	1080
TTTTAAATTT	ATTTTATTTT	TTTTTTATTT	ATTTTATTAT	TATATGTAAG	TACACTGTAG	1140
CTGTCTTCAG	ACANACCAGA	AGAGGGAGTC	AGATCTTGTT	ACGGATGGTT	GTGAGCACCA	1200
TGTGGTTGCT	GGGATTCGAA	CTCTGGACCT	TCCGAAGAGC	AGTCGGGTGC	TCTTACCCAC	1260
TGAGCCATCT	CACCAGCCCC	TTAAATTTAT	TTTTATCTTA	TGTCCATTGG	TGTTTTGCCT	1320
GCATGTATGT	GTAAAAGTGT	CAGAACTGA	AGTTACAGAC	TGTTGTGAGC	TACCATTGTT	1380
GTGGGTGCTG	GGACTTGAAC	CTGGGTCCTC	TGGAAGAGCA	GTCATTATTC	TTAACCACTG	1440
AGCCATCTCT	CTAGCCCTCG	TTTTTTAGTT	TTTTTTTTTG	TTTTGTTTTG	TTTTTTGTTT	1500
TTTTAAGATT	TTCTTATTTA	TTATATGTAA	GTACACTGTA	GCTGTCTTCA	GACACTCCAG	1560
AAGAGGGCGC	CAGATCTCGT	TATGGATGGT	TGTGAGCACC	ATGTGGTTGC	TGGGAATTGA	1620
ACTCCAGACC	TTTGGAAGAG	CAGTCAGTGC	TCTTAACTGC	TGAGCCATCT	CTCCAGCCCC	1680
GTTTTTTAGG	TTTTTGAAGA	CAGGGTTTCC	TGTGTAGCTC	TAGCTGTCCA	GGAAGTAGCT	1740
CTGTAGACCA	GGTTGGCCTC	AAATTTAGAG	ATTTGCCTGT	CTCTCTGCCT	CTCGAGAGCT	1800
GGGATTAAAA	GTGTGCAGCC	CAACAATCTA	CTCAAAGTAG	GTTTTGAAAA	AGCTTTCCAT	1860
ATTAGGAGTT	AACTAGCTTC	ATTTCAGAAA	TACTGCATGG	AATTCAAATG	TGGGACCATT	1920
CATAGCTACT	TTGGTTTTCC	TTCAGTGACA	GGCATTCCGC	ATGCCATTATTA	GGGAAGTCAA	1980
ATGGCCTGGA	GAAGTCATCC	TGGGTGAGAG	GGCTAATGCA	TTTTCAGCTT	GACAGACACT	2040
GTCAACCTAT	GCAGACAGTC	TGCTCCAGCT	CAGATGTCAA	TTGCATGCAG	ACCTGCAGTC	2100
AGACGCTAAG	CTCCCTACCT	ACTCTCCATC	AGCTTAGATG	TAAGGGGTGC	TGGAACAAAG	2160
GCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTT	TCTTAGAATT	AGTATTCTAT	2220
TTTATTTTAT	GTAAATTGGT	ACTTCACTTA	CATGTATGTC	CGTGTGAGGA	TGTTGTATCC	2280
TCTGGTACTG	GAGTTATAGA	CAGCTGTAAG	TCGCCATACA	GGTGCTGGGA	ATTGAACCCT	2340

GATCCTCTGG	AAGAATAGTC	AGTGCTCTTA	ACCCCTGAGC	CATCTCTCCA	ACCTCTTGCA	2400
TATTGAGGAC	AGGGAGGAAT	CACAAGCCAT	GTAGGGTGCC	TGGGCTCTGA	GGTCAACAGG	2460
ACCATAGCCT	CCTTTCTTTA	TGTGCCTTTC	TTGGGGTCTC	CCTATAGGAG	TCGTCTTCGT	2520
TGCCTCTTTA	CTGTCTCATT	GATCTGGGCT	AAACTTATGC	AGTTGGAAGG	AAAGATCAAG	2580
CTGGTCATGT	TTAAAACATG	AAACAGCCTC	ATCAGTTCCC	TTCCTGTTCC	CGTCTCCCCC	2640
CCCCCTCCCG	CCCCCATTTT	GAGAGGACAG	GAAGGTAAAA	TACCAAAGTG	TCCTATTTTC	2700
CTCCAAATAT	CAGGCTCAAA	GGACTGAAGA	GCTGACTTCA	GATCCCAAAG	CCACTGTGTT	2760
AGGAGGCACC	TGCTTTTTTAG	GTCCTAAGCC	TTCCTGAGCC	TTGCTATTGG	GTATTCTTTA	2820
CCAAGACCCT	CAAGGATCTA	GGCAAGAACT	GGGCAGGATC	TGTATGTAGC	CCATAGTTAG	2880
ACCTAGGGCA	GCTGAGACGC	CAAAGGGGAG	AGTTTCCTGA	GGACAAAAGT	GTTCAAACAC	2940
AACTGGGTGC	TGGTTGTTGG	GCTACTCGTG	GAGGTGTGGT	GTGTGTAAAG	GAGGCTGTTG	3000
AATTTCCAGA	AGGCTGGTTC	CACAGTGTAG	AGTCTACACT	GGGGACTTCC	CGAGACGCTG	3060
AGCCTCAGAT	CTAGCTTCTC	AGTCCAGGCC	AGCTGATGTG	GGGCTGAGGA	ACAAGGATGG	3120
ATGCCATCTA	TGGCCCTGCC	TTGCAGGTGC	AAAGGGCCTT	TGGCACCATC	TACAGATTGA	3180
GGGCAAGACA	GGGCTGGTTC	TTCCTCCTTG	CTCTCGCTGC	TATCTGCCTC	GCCTGTAGGC	3240
TCTCTGGGCT	CCTTTTTTGA	CTGACACGTC	TGAAGGAGCT	TGGAAACTGT	GAGGTCCAGG	3300
CCCCATAGAG	AATCATGAAG	GAACAGGAAT	TCAACTGGAG	CTCCGCAGCT	GGTTAGGCCT	3360
GCGGTCACCT	GGAAACAAAG	AGGCCATTTA	TTTTTTCCTT	TGGTCTTGGA	CAAGGAAGAG	3420
AAGGGGCTTT	CTATAAATAG	AAAGACAGCA	AAAAAGAAAA	TAATAATAAT	AATAATAATA	3480
ATAATAATAA	TAATAAAAAC	AATAACAAAG	CCAGCTCTTC	CAGACAGTGC	TCATGTCTTT	3540
AAAGGTCTTT	AAAGGTCTGG	AGTTCCCAGC	AATTAAGTAA	AGGACCAAGA	CCTCAGGGGT	3600
CCCCTATCCT	CAGCCCGTGG	GGAGGTGGGA	ACCATACATC	GATCCCTCGG	TTTATATATA	3660
GCCTCATCGC	TGTGGGGCTC	CGAGGTTGCC	CCCAAATCT	TGCTCACCTG	GAGGACCCCT	3720
GGGTGTCCTC	GCCCAGAGGG	CGCTGCAGCC	TCGCACGTAG	AGAACTAACA	TCGCCCTTCT	3780
CCAGGGCAGT	GCCTCCGGAC	TCCGGACCAG	GACATAGTAG	CGAGTGCACC	TGGGTCTCCG	3840
TCAGCTACGC	ATCAAGGAAG	GTGCGACGCG	GGAATTACAG	ATTGCCGGCA	CTCACCAGTG	3900
CTCAGGGGAG	GAAGGTGGGA	CTCAGACCTG	CAAGAGCTGA	AGAGTGGGGT	GGGCTTCGAT	3960
CCTAGGAGGC	GTGGAAGGGG	GTGTGGCTGG	ATCCCTGGGG	GGTGGGGCGC	TCCAAGGGGC	4020
GGGGCAACCC	AGGGGGCGGG	GCCCGAGGGG	TGGAGATTGG	GACTACCCAG	GCCCGCGGAG	4080

CTGGGGGTGG	GCGGCTAGTT	TTGCAACTGC	AGAGCCTTTG	GGTTTATTAT	AAGGCGGAGC	4140
TCCGCGGGAG	AGGTGCGGGC	CAGAGGAGAC	AGAGCCTAAC	GCAGAGGAAG	GGACCTGGCA	4200
GTCGGGAGCT	GACTCCAGCC	GGCGAAACCT	ACAGCCCTCG	CTCGAGAGAG	CAGCGAGCTG	4260
GGCAGGAGCC	TGGGACAGCA	AAGCGCAGAG	CAATCAGCAG	AGCCGGCCCCG	GAGCTCCGTG	4320
CAACCGGCAA	CTCGGATCCA	CGAAGCCCAC	CGAGCTCCCCG	CCGCCGGTCT	GGGCAGC	4377
ATG AGA CGC GCG GCG CTC TGG CTC TGG CTC TGC GCG CTG GCG CTG CGC						4425
Met Arg Arg Ala Ala Leu Trp Leu Trp Leu Cys Ala Leu Ala Leu Arg						
1	5		10		15	
CTG CAG CCT GCC CTC CCG GTGAGTGTGG CCCGGGGCAG GGCTGGGAGG						4473
Leu Gln Pro Ala Leu Pro						
20						
CGGCGGGAAG	CCGGGACTCG	CCACTCGCCG	ATGCCATGCA	GGCGGCAGCA	CGTGGAGGGG	4533
GAGGGGAGCG	GGGACTTCTT	CCCGCGCTGC	CTGGCGGATC	CTGGGATGGT	GAGCCCTTTA	4593
ATGAGGACTC	CTGTCCCAAT	TCCTCTACGG	TCCGTGGATG	CCAGGAGGCT	ATCCCAGCTC	4653
GTGGTCCGGG	CGTCCTGCAG	AGTGGAACCT	CCATTGGTTC	CCCGCTCCCA	ATTAAGTAAA	4713
ACGACTCCAC	AGGGGTCTGA	GTCGCCGGCC	TTAGGCGCTC	CGCCGGCCTT	AGGCGCCGCT	4773
TGGAGTTGCT	CTCTCCCGTT	GCTGTCTTGC	TGGCCATCTC	AGCGGCCTGG	CCTCCGCCAG	4833
TGTCCCGGAG	GATGCAGTGG	CCATGGCCAA	ACGCCTTTTC	CATAGACCCT	AATTCAAACC	4893
AGACTGCAGG	CTGCACCCCC	AGCGCCGCGG	AGTCCGGGCG	CTCGGCCCTT	TGCACCGGGG	4953
CAAGTTTGGG	CACAGCAGAG	CCGGCGCGGG	AACAGGGGGA	AGCTGACGTT	CGGGGTGGCG	5013
GGAGGGACGG	GATTAAGGCT	GTTTGTGGGA	CACAAGAGGG	TGGCTCAGGG	ACTTCGGTTT	5073
TTCTCTGGCT	GCCCCAGGTG	AGCCGGGCGG	AGCTGGCAGC	GGGAGGTTCC	GGGAAGTTGG	5133
CTTCAGAACG	CTGAAGACCC	TAAGAACCCA	ACTTTGGGGT	CGCTGAAGTT	GTGCTGCCCC	5193
CGGAGGGCCT	CCTCCGCATG	GCCCGCGCGG	GGGACCCTCC	CCGCGAGTGG	ACCCCGGTAC	5253
GGCTCTTCCC	CTCCCCCGAC	TCGGCTTTGT	GCTGAAGCCG	CGCGTAGGGA	AGGCGGGTCC	5313
CTTGCCCCGC	CCAGTAGGGC	CGCGGGGAAA	GAGGGACGAA	CGTGGAGCTG	GCGACTGGTG	5373
GGGGAAGCTT	CTGGGTAGGA	TGCAGCCATC	CACCTTTGGT	GGGGTCGGTC	TCTCTAATCA	5433
GCGGCTTGGC	GACAAAGAGC	TTGGTCGAGG	GTACCCCAAG	AAGTGCTCTC	CCGCCCCAAG	5493
CCGCCGTCGC	TAGCCCGCCT	TCCCAACGGG	CGCTTTGTTC	TCGGCCCCCTG	TAACCCTTCC	5553
CTGGGAACCG	CCCCGCAGCG	CTGGTCCTTG	ACGTGGGCCG	GGTCCTGGGT	CGCCGCCAGT	5613
GTCAGCGCTG	CCCTCCGGTG	TCCACGCCCC	TAGCCCCCGC	ACCCGCTGTG	AAGTCCCGGG	5673

TGTCCTTTCC	ACTGGCGCTT	TGCCCCAACC	CTGGAAGGCA	GAGGCGAGGT	GCGGAGCCTC	5733
AGGCTTTATC	CTCCCGGAAG	TGGCAGTCTC	CCACCGCCAC	ATCTGGTCTG	CTTAAC TTCG	5793
ATAGTCCTGG	CAAAGGCAGA	CACGTGCACA	GGGAAGGAGA	GTTGAGCGCT	GGTAGATACC	5853
AAGGTCGTGT	ACAAATAAAG	TGGCACACGA	CACGTCCCCA	GTCACTGTTA	ATGCATTGCC	5913
TTGCTCCTT	CCCAGGTGGC	TGGTGCTCTC	CATCACTCTG	GAGCCCAAGA	GAGGGCCTCC	5973
ATAATTGTAT	TGCCCATGAG	TTGGGGTTGT	GTGGGGGCGC	CAAATCAGGG	TTCTCTGGGA	6033
GGGCTATGAA	TTCCGAAC TG	AGTCTCCTGT	GCACTCCTGG	CTTTAAGGTT	CAAGAAATTG	6093
TTTGAGGGTT	GTGGTTTTTG	TGGGACTCAG	ATTATGCCTG	GAATCATAGT	TACCACTGTG	6153
GAGAAGAAAG	TGGAGCTACT	TAGCATGCCT	CCCCGGCCCC	CCTGGCATT A	CCTCCGGCTC	6213
TGTTCTCTAG	GCCCAACGTG	AGGCCTCACT	GGGGCAGTAC	AGATGCAGTA	CTGAATTTCT	6273
TTCCAGCCAG	GATCTGGAGA	GGTGGTGTT C	TCTTCCCTGG	TGTCTTTAGA	GAGGCAGATA	6333
TTCCTGTGAC	CTAAGCCCC T	CAAGCACCCA	TTAATAATGC	TGAGTAGACA	ACTAGAGGTG	6393
GCGTTTTCCG	GAAC TTCCTG	TGTGCTGGCC	TGGGAGGTTG	AACCCTCTAG	GAAACAGGTC	6453
TAGGAAGTAG	AATTATCTCA	ATGGAAGGCT	TCCTGGAGGA	AGAAGATGAG	CTGAGCCCCC	6513
AGGTCACTGT	CTGAGCTTTA	GGATCAGACT	CCCACTTGGA	GGCAAGAGTG	TTCGTTTTAC	6573
TTTTTTTTTT	TAAGTTTAGT	TTATTTTCTC	TCTAACAGAA	AACAAACAAA	CAAACAAAAA	6633
AAAACCCAC	ATTGTTTAAA	AGTGGGTGCA	TAAGAGTGAG	GACATATTCA	GAGCTTCCCC	6693
TTTTCTTGAA	AAATGAAGGC	AGCTGGGATT	TACTTAAAT	GAGAGCACAT	ATCACAATTG	6753
CCAGAGAGCT	GGTCCCTTTC	TCAGGGCTCC	CTAAGCTCCT	GTGGGAAGCA	GGTCAGACAG	6813
CCCTGGGGAC	CAGAGAGATA	GGGAGTGCTT	TTGGGTGCCT	GCCTTTGAAT	GGGGAAGGGG	6873
GGGGGAGCTG	CTGGGATCAG	AGGCTGCTAG	CACTACTCC	CCAGAGACTG	AAGCAGGTTT	6933
GTCCCTCAGT	GTCCTGTGGT	CTTCTGTTTC	TCCTATATAG	AATAGGAGAA	ATGGTTATTT	6993
GCTCTGGAAT	AGTGACTTGC	TATTTGTTCC	CTTTCTTTCC	TCTCCCTTAC	TGTAATCATT	7053
TGGACTAGTA	GAGACACTTT	CCCCAGGTCT	GGCAGAATGG	GAGGGAGTGG	GGGAGGCCTG	7113
TGCTTG CATG	ATGTC ACTGC	TGGCTTCAGC	TCTCCAGGGA	GGGTGGAGTT	GGTTGTAACC	7173
TACCTGTGGC	TCTTGATGGG	CCACAATAAA	ACCTCATTA A	CACACATTGG	TAGGGAGAAG	7233
GGACTGGAAA	GAATGATGGG	AAAGATTGAT	GTTTTTCCTT	TTTTTTTTTT	TTTTTTTTTG	7293
GCAGTACTTT	CTAGATCTCC	CCTCCCCCTT	GCTGCAGCAA	AATTTTGGAT	TCCTGAAGTC	7353
CTTTGAGAAT	GTATAATGGT	AGCCAGACTT	TTTTTTTTTC	AGTCAGCTCA	AAATTGCCTC	7413

CTTATAAAGT	ATCCTTGGTT	GTTTTTTGTT	GTTGTTGTTG	TTGTTGTTTT	GTTTTGTTTT	7473
AAGACAAGGT	TTCTCTGTAT	AGTCCTGGCT	GCCCTGGAAC	TCAATATGTA	GACCAGGCTG	7533
GCCTCAAAC	CAAAGAAATC	CACCTACTTC	TAACCTTCAG	TGCTGGGCCT	AAAGGTGTAG	7593
GCCACCAAAA	GTGCTCAACT	TTTACAAAGC	AGTCTTACTT	TGAGCAGGAT	TCTGAAACCC	7653
TTATTTTCCTT	TCTGTTATCT	TCAACAATAC	ACTGCTAGGT	GTATTTAGTC	CCTCATGATG	7713
CTGGGCCTCC	TCAAGTGGCG	CCAGGTCAAG	CAGTCTCCTG	GTTTTTGGTG	GCTCTGAAGA	7773
AGACTGTGTC	CCAGTGACTG	GCAGTTTGAA	TTCGGAGCTT	CTCTTTTCCT	TCTCAGTCTT	7833
TGGCAGGCAG	AGTGACACTG	GTGTGCCCAA	GCCTGGAGCT	TCTCTGTTTA	ATTCTAGTTT	7893
ATTTTCTTTA	TCAGACTGAA	AAACAAATCA	GGTTGGTTAT	AATTCTTATA	AACACGAAGG	7953
TCTCACCTTT	GCGTACGTCT	CCGGCTGTGT	GGGTCTGATG	TCCCTCGGGA	ATCTCTGTTG	8013
AGGCTGCTGC	AGTGTGTGTG	CGTGTAGAAA	GGGCAAGGTA	GAATGGACAG	AAGCGTGCTG	8073
CCCACCCAC	TGTCCTGTTT	CTAAATGATG	AAGCACTGGC	CCGGTGAAGA	GCCTAGAGAA	8133
CTCCCTCGGT	GGGAGATGCA	CACAATGCCA	GGAAGCACAC	AGGAGCTTGA	GTTCCAGCTT	8193
GGCAGTGTCT	TCTCTTTGGT	GACTTTATCA	GCTCCAGCTG	CCCTGGACTA	ACAAACAAGG	8253
CTAGCTCACT	CTCAGTATTG	ATAATCGAAG	GTCCTTGGTT	CTGTTTGAGA	CTGATCCTCA	8313
CTCGGTAGCC	TTGAACTCTT	AGCAATTCTC	CTGTCTCAAC	TTTCAAAGAG	CTGAAATTAC	8373
AGACTCGAGC	CACCATATGC	GACTGAAACC	TTGTTCCCTA	TCCTTGACTG	TGAACGACTC	8433
TTGGGTTTGG	TTCTTTCTCC	ATTTCTTTAG	TGTATGTTTT	AGTTCGCGTC	CTACATAATC	8493
TATTGCCCAT	ACTTAGAAAC	AACAGGTTAG	AGACAGCATT	GGGTCCAGCA	GAGCCTCACA	8553
CTGAAGCTCA	GTCCTGCCAC	TGATTTACCG	TGTCAGCTCA	AGTGACTCAC	TTCCAACTCC	8613
TCTGCTCCCC	ATCTGTAGAG	TAGACATCAC	CATACCTGCT	CTTTCTGCCC	ACATTCTGTC	8673
ATTAACATGT	TCATTTTATA	ACGATGGTGC	AAAAGTGCTT	TGTAAGTAAA	GTGCTGGGGA	8733
AATGTTAGCT	GTCGATAATG	GTTAGGGTTA	ACTTTTTTATT	GAGTGCCTGT	TGTGTGTGGG	8793
GTTGGGTGGG	GTTTTTTTAG	AGGCTTGGTA	GTTTTCTTAC	TTCTTTCCTA	CTTAGCTTTT	8853
CTTCCTAAGC	CTTTATGGTA	TGTATCATTG	CCTGATTGTT	TGAGTGTGTG	CACTGAGGCA	8913
CGCCTGTGCA	TGTTTGAGAG	TATGCTTGTG	CGTGCTCTCG	TGCTCACATA	TGTATGGTGT	8973
GAATACACTG	TAGAGTGCAG	GCCGGCACAC	TGGGGCTGGC	TGAATCCTGT	GAGCCCTGCC	9033
TGGAGTTTGC	AGATCTTCCT	TGGACACTCC	TGCTTGTGAG	CATTTTGTGT	GGAGTGACTG	9093
TTTAGCTGGC	TGTAGCCTAC	ATTGTGCCTT	TGGGTAAACC	CTGAGTATTG	GGAAACACCC	9153

TGGGCTGTGG	CTGTGTGTGC	CCGACGGTTG	CTTGGGTACA	GCTAAGAACT	CTTCATAGAA	9213
AGTTGAGCTC	ACATGCTATT	AGTATTAAGT	GAGTGCTAAG	GAACCTGTCT	TGGGTGGTAC	9273
CTGCTTGCCC	TCTCATGCAG	TTTATCTTGA	GCTTGCGCAA	CACACTTACA	GATTTAGTAG	9333
AGCTTTTGTC	AGCCCTGGGA	GGTGGGTTTC	GTGGCCACAA	GTGGGTAGCT	TGGAATCCAA	9393
GACTCCTGGC	TTCTAGGTTG	CATTCTCCTG	TGGTTCTTTC	CAAGGGAATG	CTAGGGGAAC	9453
ATTTTGGACA	TTAGATTATT	TCTAGTCCCA	AAGCACACAG	AACATACTGT	TTCTTAATTG	9513
CCTTTTTTTT	GTTTTCTCT	CAATCTGGTT	TTGAAGTGTT	GGGTTTGAAA	ATTGCCCCCT	9573
GAGAGCCTGC	CCTAGTGTGT	GCAGAGGGAA	GATAGTGGA	CAGGAAGTCT	GTAAGAAAGTA	9633
TCTTCCTTTC	CAGGACCTTG	TGCCCCGGAG	CAGAGTCAGC	ATGGTGTCAT	ATCGCTTTTG	9693
GCTATTCCAG	AAGAGATGAG	GTTTTAGGTG	AGAATGAACC	TTTTAGAACC	TTCTAGAACC	9753
TTCTGTTGAG	TATGACAGGA	ATGCCCTGAA	TAGGGTCCGA	AGTGCATGGC	CACCTGTTTG	9813
TCTTTTCCAT	AAGCAAGCAG	CTTCAGGTAC	AGACAATAAG	ACTAGGTTCT	TGGAGTGAGA	9873
CCCTGCACTT	GGTGCCATTT	CAGCTCCAGA	TGGACACTGG	AGGTCCCTAC	ACAGCAGGCT	9933
CTGGGATGGC	TGGCTTTGCT	ATGTACTGTT	GCCTGCTCTA	CAAGAGCTTC	CCAGGTTACT	9993
AGCCTTTGTC	GACGCTGGGC	TCGCTGGCCA	GGCTTGGGCA	TTGGAGAAGG	GACAACTTGC	10053
CACCTGGCAT	AGGCTGTGTG	TTTGGAGAGT	CAGGAGGTCT	GGTGAAGCCC	GCAAGTGGAG	10113
GCAAGTTTAG	TGGGACTTGA	GGAGAGCTCA	GTAGGAAATC	TCTGGGCTAG	TGACAGGCAG	10173
GTGTGGTGGT	GGTGGCGAGG	TGGCGGGTCT	AGATCTCCTT	TTAGAGATTT	GCCTAGGGAT	10233
CGTCCCTGCT	GACTCTGGAA	CTCAGAGGCC	TCCAGAGGTG	TCTCCTCTGG	GAGCCTCTCA	10293
AGGGTCTCCC	ATCTCCTACT	GTTTATGGCT	TTGTGGGCTA	CCTAATTACA	TAGAGAAGAT	10353
ATGTTCCCTCT	GCCTCCAGCC	CTGGAAAGTT	CTGCCCAGTG	ACTCACCTGA	GCCTGCAGCC	10413
ATGTGTGTAC	ACAGGCGCTC	TCAGGGGCTT	CTGTCCTGCT	GGCTTCAGCC	TTTCTAGCCC	10473
CTGGTGTTCT	CGGCAGTGGT	AGCATCTGGG	AAACCGGGTC	ACCTCTTATT	TGCAGCTCCC	10533
TCCCTTTCTT	GGTGTCTTCC	CCCTTTTTTAA	CTACTGGTCT	GATGGCCTTA	GACTCATGCT	10593
GAAATTCTCC	TTTCTTTTGT	CCTAGCCTTG	TCTCTGACTT	CTTGTGATCC	TCTGGGCCTG	10653
TGAAATCCGC	TCAGGGGCCT	CCATTTCTAA	CAGTCACACA	CTGGTGGAGA	GACCGAGTCC	10713
TGGGATGGTG	AAGCTAACCC	TGCTGGGCTT	CTCAAGCTTC	ATTTGGTTTC	TCTTTATTCC	10773
TTCTGGAGGT	ACTGCCTGCC	CCAGGGGAGT	CTCAGACTAG	ACCACTCTGG	AGTTGGAGGT	10833
GGGGCAGGTT	TTCAGATCAG	TGCCCTTGGC	ATTCGTTGTG	GGAATGGGGT	GGATGGGGCC	10893

TCTGGGCAAG	GTCAGGCTGG	GGGTGGAGGC	CAGGTGATGT	TCTCCGCACC	CACACCCAGG	10953
CAGCCTGGCA	CCCTCCCCAA	GGTCCGCTCA	TCAGCAGGAA	TGAAAGCAGT	GCCGGGCAGG	11013
TTGGGGCAGT	GGGCAGGTGG	GCGTGTTTAT	CGCTGTGCTC	ATCAGCTGAG	TCACGATGCC	11073
AGGCCCCACA	AGTCCTCCCT	GGAGGCTCAC	CCCACCCACC	TTGACCCACC	AGCACCCACT	11133
AGCAGGAGGT	AGGGCAGGGC	AGTGAGACAA	GACCAGCCTG	GGGGTCTGAG	AGGCAAAGGG	11193
GAGTTGTTCA	TGACCTGGCT	GTGCATGGGG	ACTTGTGGGT	GTCTCAGATA	TCTCTGCTGT	11253
CCAGGAGGAA	GCTGTCTTAA	GTGCCAACCT	GCCTAGAGCC	CCTGCTGGGT	GCAGGAAATG	11313
CACAAGGGAG	AGTGCCCATC	CATGGAATAG	GCCCATGGAG	CTAGACCAGT	GACAGTGACA	11373
GTGAAGTCAG	CCCCCACCTG	TGTCTTCCGA	GCCAGCTGGA	GGGTTTTTAT	CTCAGATTCT	11433
GCGAAACCAT	AGAATCTAGT	CAGGAGCCTA	GACTGCAAAG	CAGGCTTCGT	TGATGCTTTA	11493
ACTTGCAGGC	TTCCTGGGTA	TGAGGGATAC	TTAGAAAGGT	CCCGCAGGTA	GGGAGGGCAT	11553
CAGGAAGTAG	AAGAGGGCCA	GGCACTTCTA	TCTCCTGCAT	TGCCCCCTTC	TCCCATCTCC	11613
AAGGATGGTA	AAAAGAACCC	TTCCAGTACA	CTGACAGAGA	GGAAAACCTT	TCATCTCACC	11673
CCATTTGGAT	CTGTCGTATC	AGCATGTGCT	GGCCCTGCTT	CCATACCAGA	GGTGGCTAGA	11733
GATGTTCCCT	GGGAATTCAC	TGGTTGGGGA	CTTGAGTGTA	TCAGAGGGGC	ACAAAGTAAC	11793
ATTAActCTG	GTATCCTCTG	CAGCAAATCG	GAGATCCCCT	CTCCTAGGCG	AGTTCTCAGT	11853
GGATATGGAG	GTCAGGTTTG	GGCTTGTAGG	GCCCCAGCAA	GAGTCGTTGA	TGTCACTCCA	11913
GCTTCTCCCG	AGGAAGATGA	GGGTGCTGTG	TTGGGATCAC	ATCTCTCCCT	GAATGGCATG	11973
TTGGGGAGGG	ATGGAGCCCT	TGCTTCTGAC	CCCTAAGCTT	GGTCTTTAGG	TGGCCACAGT	12033
CTCTGGGTTC	TGTCCTACCT	CCCTGCCCTT	GTGTGCTTCA	AAGGCATGCT	AAAGGGACTC	12093
TCGGCCATTC	CGAATGGCAC	AGTGTTCCCT	CTGTTCTCCC	ACCCCCAGAA	GGAGGCAGGC	12153
CTGGATTGTA	GATTCCTAGA	AGTAAGTGGC	CCTGAGCATG	CTGTTGATGA	ACCTGGAACC	12213
AGGCAGGCTG	GGCATCCTAG	GACCTGTCTT	TCCATAGAAG	TCTGAATCAG	TCTACCTTTG	12273
GGA CTGAGTA	AGGGGCTCCT	CACATATCAG	CTGGCTAGTC	CATCTTGGCT	GATCTAAACC	12333
ACATTAGGCT	GAAGAGAAGC	ATGGTGTACA	GTCTGGTCCA	CCCGAACCAC	ATACTGGCTT	12393
TATCAGTTCT	CGTATAATTT	TGCAGGTAAC	TTTTTAGCTC	TAAGCCTGTC	TCCTCATCTG	12453
TGAAATCGGG	TCCCTCATAT	CCTGCCCTAGA	AGGGCTTTTG	AAAAGATTAA	TGAAGTAGTA	12513
TGCCGAGTGG	TTGGGGTTCT	CTCCTTGACT	GGAGCAAGTC	TCTAGGAGTA	CTAAGGATAG	12573
CCTGCTGTGT	GCAGCACCCC	CAGGGACTGT	GCCTGAGTAG	GAGGGTACAG	AGTCTTCATG	12633

TGAATGGCCC	TTCTGGTCTT	CCCCGAAGT	TAGTGTTGAT	GTCATAGAGT	CTACAAACAT	12693
GCCTTTTGTG	CTTCCTCAGA	AGTCCAAGCC	TTTCCTGGCA	GACCAGACAT	TCATCTCCAC	12753
TGAGCCTCTA	TGTGAGACTG	GCTCCTGGCC	TGAGCTGTGT	GGGCTGAGCT	GGCGAATGGG	12813
AAACTAGAC	ACCTGGGCAC	CTGGGTGGGG	GCTCGGGACA	GCAGTGTTTC	AGTTGTAGGC	12873
ACTGTGCCCC	TGCCTGGAGC	TTCTGACTGA	AGGTTACCCT	GAGAGGAAGC	AGGTTCCCTA	12933
TAGACACTAA	CATAGCTGGG	TCAGAGTGCA	AGGTGGGTGT	GCCCCTGCCC	TGACCCATTC	12993
AGTGCAAAGG	CTGCTCTTCT	GGGAGTGAGA	GCTCTGACAG	GACTGTGATG	GCCGAGGGGT	13053
CTCAGAGCAA	ACCTGCCTGG	CCTCTCCCCA	CTCTGATGGA	TATGTGCTCT	TAAACAAGTG	13113
ACTGTCCACT	TTGCCTCAAT	TTCAACATCT	GTAAGATAGA	TAGGGCGTTA	TGGTCTGAAA	13173
ATGGTTTTAA	AGATTAGTTA	GCTAATACAG	GGAAAGTGCT	CTGACAGGTA	CCTGGCACCT	13233
TACTCAACAA	GTGGCTGGAG	TGCCTGATTT	CCTAAGGTCT	CGACCTGTCC	CTATGCTTCA	13293
AGTGCCCCTA	CAGCCTTGGT	CAGGCCCTTA	GGTTCTCCCA	CCCACCGCTG	GCCCCAGGAC	13353
CTAGACTGCT	GGACCCTGAC	CCCATTTTTC	CTTTAAGCCA	CCTCTGCGTC	AACTCTAAAA	13413
GGCGGTGGAG	TTGTTTATCT	AGGCTGTGAG	GTGTCAGAGA	AAGGACCTGG	GCCGCTTTGT	13473
TCCTGTGTGG	GCTGGGGCCA	CTCCAGGAAC	TGAGAAAACC	ACCCACCTTT	TCAAAAACAG	13533
CCTCTTCTCA	GAGTCTGGCA	CCTCAGCTAG	CCACCATGCT	GTGGGACCAC	TCCCAGCATG	13593
CTCTGCCTTT	GGTTTGTTTC	CCAGGGGCCT	CAGTGCCTTT	TAAAGATGCA	CAGGCATCTT	13653
TAGTTCAAGG	GGAAAGAGGA	AATGAAGTGT	ATTTGCTGGT	GGTGGTATTC	CTGTCACTTG	13713
CATTCTCACA	GAGGCTAAAG	AAATTGCTC	TTTGTATCTT	CTAGTCTCTT	CTTTATGATC	13773
TTTTCCCATC	TGTTGTATCC	CAACTGCAGG	GCCCCAGTTC	TAGAATTAGC	CCCTCCCCCA	13833
TAGGAAGCCG	ACTTATGCTA	TAATGTGAAT	GACAAGTATC	CTTTAGCCCT	TCCCACAGGC	13893
ATTTTAATTT	TCAAAAGGGC	ATTGCACAAC	CGCAGAGACA	CTAAGAAGAG	AGGTTTGGTG	13953
ATCAGAGTTA	CAGCCCCAGC	CTCCCAGCTG	GTGGCCCGGC	TGGTGCAGGT	GTGTCGAAAG	14013
CAGTAGTTTC	TGCTTCAGTG	AAACTTGAGG	ATCCTTTATT	TAGCCAGTTC	AGGGGCGGAA	14073
TGGCCATGCG	AAGTCTATGT	GTCACAGGTG	TCAGGCCCCC	ATATCCTGCT	GAGTCTAGAA	14133
TCAGCTACGT	AGCAGTTTTG	GGGGTATTGC	CAGACTGGGA	GTTTACATCC	CAGAAGCGAG	14193
AATGGTGGGG	TTCCTATACT	GCTCCAGACA	GGATCTTTCC	CCCAAGTTTG	TCAGCCACCT	14253
CTCTTCAAGT	CCCTTGGCTC	TGACCAGCAA	GACGTATCCA	AAAGAACTG	AGGAGGCCCT	14313
TCACTTCTTT	TTAGGATAGT	GTGGGGCCAG	CATGGTGGGG	GTTGGGAATG	GCTTTCTGTC	14373

TCTTCCATCA	TCACAGGCTA	CTTCCCAGAG	ACACTTTGAT	TCTGGGCATC	TCCAGCAGTC	14433
ACCTGGCCCA	CAATGCTTTG	CTGCCCTTTG	CTTCAGCCAC	TGTATCTGGT	TGTCCCTTGA	14493
AGGTGAGCCA	GAGCTCCTAG	GCAGAGAGCA	TGTGCTATAC	AAAGCCGTAG	GCTGGGCCCT	14553
GGGAACCTTC	TTGCTGTCAT	CCTCCTGTCA	AACCCCTATG	GTATGGTAGC	CCACATAAGG	14613
CTTG TGCAAA	AAACAGGCCA	AAACATAAGT	TATCTTTTCA	CTCTATCGGG	TCTTCTCATT	14673
TTCCCATGGT	ACGTTTCGGCT	GGCCAGGCC	AAAAGATTTG	AAGAGAGGTG	GCTGGCAAGT	14733
CTAGGGGAAT	AGGTCTATCT	GGTTCCTCC	AGGAGCAGTG	CCTAGTGAGA	GGCTGGGCTG	14793
GGCAGGGCAG	GGCCCCTTGC	TCCACATTGC	CTGAAGTCCC	GCCCTGCCCG	TCCTGGCTGG	14853
GATCTGGCAG	GTCTTCCAGC	TCCACACCCG	GCTCTCAGCT	GAGCCTGCTC	AGAGACTAGT	14913
CCTGGCATGT	GGGTTGCAGG	GCTGGTTCCA	GCTCCACCAG	GAGGTATGGG	CGTCTGGGTA	14973
CTCATGGGAC	ATTGACCTGT	AGTGGGTATG	GAGAGTGGAG	GAATGGTACA	GGCAGGTGTG	15033
CTGGTGCTGA	CGGACTTGAC	TCCGGCATTG	ACCTTGGCTT	GCAGTCTGGT	GTTAAACTAA	15093
CAGGGAATGC	TGACAAAAAA	GACAGTTATT	AAAACCAAGA	CAGGATACTG	CTTTCCCACT	15153
CAGCCCATTC	CCAAGAATCC	CCAAGACGTA	CAGGAAATGT	GCAACAGCAG	TGGGAATTGC	15213
TGAGTTGGGG	GATGTGGGTG	AGCTGTGTGC	TCCCAGGGAA	TTTTGGGAAA	TTCCCTCCG	15273
TTGAAATGCT	GTCAGGGTCT	GAGCCTTGGA	GGTGTTTTTG	GGGTGCTGTG	CTCCCCAGCT	15333
AAGCAGCTAA	CAGTCCTCTT	TACCTGCCTT	GTCCTCACCT	TGCCCCACCC	TGGGTGGGGC	15393
CTCTCGTTCA	CTCCCTGCTG	GGTCACCAGT	ACTTCAGTGC	AGGTCTCAGC	TTGATTCTTG	15453
GTGGAGAGAG	AGAAAGTTGA	TAAATCAGGG	TGCCTGTCAG	CCGGAAATTT	GGGTGTGTCC	15513
TGAAGGCACC	AATGGGGGCC	CTCCCTTCTG	GAGGTGGCTT	TAGGAAGGGG	TTTCTGGGTC	15573
TTGAGGCCTC	CTTACAGTTT	CTTAGCTCCA	TGGGAGAGAA	GTGAGGAGTT	GGGTATCGTC	15633
ACCCAGCAT	GAATCTCTGG	TCACCTCTCA	GCATGCACTG	TCCAGCCTGA	TCTTTGAGTG	15693
CCATAAAAGA	ACAGAATTAT	CCTCTCAGAG	CACTTCATTT	CCCGCCAGCA	CAGTGGGTAC	15753
AGAGACAAGC	TGCCCAGACT	CCCAGCGAGG	GACTAGTTGA	GCCCCAGCAT	GGGACTAGTT	15813
GAGCTAGACC	TGATACAGTC	CCAGAGAGCC	TCGTTGAGGA	AGCTTTGGGA	AAATTCACCC	15873
AGCATTTTCA	CCAGGACTGG	AGGAAAAGGT	GATTATGGGA	AAGAGAGCAG	TCAAGACCCC	15933
AGGCTGTAGG	ACACAGGATA	CAAACTGAGA	GCTACCGGAT	AGGAGTAGGT	TTTAGTCACA	15993
ATCTCTCTG	TCCGCCCTAC	CCTCCAGGAG	ACATTGCACC	TTGTAGAACA	GCTGCCCCGG	16053
AGTCCACCTT	TGGGCCCCCC	TGGGTAGCTC	AGTAGTGTCA	GCATCCTCTC	ATTGACATCA	16113

GTCAGGTTAC	ACAGTGGGGC	AGCTAATGTG	AAGGCGCTAG	GCTGGGAAGC	CAGCTACTTG	16173
GGAAAACTAG	GTTGTTCCCTG	GTAGGCCCTA	GCAGGAAGGC	AGTTCCTCCT	TTTCTTGGTG	16233
GCTTTAGGGG	TCTTTGGAAG	CTTTGAATGT	TCCCTCAGCT	CGTTGGTGAA	GCAGGCCCTC	16293
CTGGTACTGT	GGTGTTTGTC	TTCGAAGAGT	GAAGGCATTG	GAAGTAAAGA	CTGATGGGGC	16353
GCCTTCCCAG	GATGCTTTGC	TTCTTGCGCT	GGCTTACAGA	GCTCTCTTGC	TACCTAGTGC	16413
CTTGACTTTG	AACACCAGAT	TCAGTCAGGG	AACAGGAGTA	GAGGTCTTGC	CTTGCTGAGC	16473
CCCTGCGCAC	TGCAGGAAAA	GACTCCTCTG	AGTGGAGCCT	TTCCTCCTCA	GGTGACTGCT	16533
TTCAAAGTAC	AGCAGCCTCT	GAGGGGGAAG	TGTCATTGTA	CATTGTGGTA	GTTCTTGGGG	16593
TCCCTGGATA	CAGATGTCAT	GCCCAGATCA	TAGGTCTGTT	TGTACAGAGG	GAGGCGAGTT	16653
CTGTAGCTCA	GAGTCCTCAG	TACCCCAGAG	TTGTGGCTCT	AGGGGTGAGA	GGAGAAGACT	16713
ACAGCCCTTC	AATCACAGGT	CTGACCTGTG	GGTAGGGGTA	GATCTCTTGC	ATACTATGAA	16773
CCTGTTTGAA	ACCCCTGGGT	ATTTGCTGTG	GAATAGAGTC	TTGGTTGGGT	AAGAATGGTG	16833
GATGTTTATC	TTGGTGTGAC	TCTCGGGTGG	GGGTGGGGGA	TATGTCCCTG	TCTTTCCCAA	16893
TGTAGTATGC	TGAGTGGACA	GAGACCGTGT	GACTGAAGCC	TGGGCTCCTG	GAACAGGTGT	16953
GTGTTGGTGG	GGGGTGGGGC	GCAACTATCT	GGGATCCAGA	CTGCTTGGGA	ATGGCTGTGA	17013
CCCAGCTCCT	TTGATAACAG	CAGCTCTTTG	TCACTGGATG	TTGTGACTAA	TGGGACTTGT	17073
TGATTCAAGT	ACTCGGCTCC	CACCCACAGA	CGCCGGGGCT	TCTGTTGTGG	CACCAGGCAG	17133
CTGCAGACGG	CCCACAAGTT	TGCCTCGCTT	TCCCACTCCA	CGAAGGTAAG	TTCCCAGCAC	17193
TGCCCCAATT	AGAGACTTGT	GAGTGGTCCC	CTCATACCCC	ACTCCCTGAG	GCTTCTCCTG	17253
GAAGGCCTGG	AATGGGGCAC	TGGGTGTGTA	CGTGCTGTGG	TTTCTGTTAG	GGTCAAGACC	17313
AGGCTGTTTC	TTACCTGGCT	CGTACCTCCA	AGTTTCCAGG	TGATGAGTCC	TGATTTTTGA	17373
AGTGAAGGAA	TCCATTTAAT	ATCAAAATTC	TGTGACCTTA	AATTTTTTTC	TTTTATTATG	17433
TGTCATTTCA	TATGTACGCA	TATTTTTTTG	TCTGTGTGTG	GACATGCTTG	TGGCGATCAG	17493
AGGACACTTC	AGAAAGTCAG	TTCTCTCCTG	CCGTGTGGGT	CCTGGGGAAT	CAAATCCAAG	17553
TTGTCAGGCT	TTATCCTGAA	AATAAAAAGT	AGACAGCCCT	TGGGATCCAA	AGCTTCTTAG	17613
GGCTGTGTGT	CTTAGACACC	ACCAGTGTTG	CACAGCTGGT	AACATGACAG	TGTCCTGGAG	17673
TGCTGATTGG	AAGCCACAGG	CCTCTGTGCA	GGGCGGTAGA	CTTCCAGGGT	ACGGGGCAGG	17733
TGGGCGTTCT	CTACAAAAAC	CTTGTAATCG	CGGACGTCTT	GGAGATGCCC	CCTAGGTATC	17793
ATGATTTTGG	TGTGTGACAC	AGCTGAACTG	TCTTCATACT	CAGGATATCA	TGAAGTGCTG	17853

GGGTGCAGAC	CACTCTCAGC	CTCAGGCAGC	CAGGACCCGG	GGCTCCATCA	GATTGCGGTG	17913
ACTACCACAG	AGGGTGGCCT	TCCTTCCGGT	CAGTGTGGGT	GTGGGAGCTG	GCAGGAAGTG	17973
GCTCCAGGCT	TCCTTTAAGC	ATCCTCTGCC	CACAGCCCCA	AACATGTTCT	TTGGCAATGG	18033
CTTGCAACTA	GAGGTGAACT	CTCTCCTGTA	CTATGTCCTG	ACCCACGCTG	CTGCATCTAT	18093
TATACCTTTC	ACACGCGTGA	TGGGTACCCA	GCGGGGCTGC	TAGGCAGGGT	TAAGCACTCA	18153
TCTTGTTTCC	TGGTGCTGAA	GCTGTGGTAA	AGAAACTGAG	GCCATTTTCC	CTTGAGAGAG	18213
ATGGTCTCAG	CCAGGTCTTT	CTCGGCCTGG	GGAGCCCGGA	AGAAAGGATG	TACTACAGTG	18273
AGTGGACACT	TGTTGGCTGA	TGGCCTTGGT	AGGTCCTTCA	CCCTGGGAAG	TGCTGTTTCT	18333
TATCTGTTAG	AGATGCTGAC	CTCAGCAGGA	CTGGAGGAAC	TGCATGGGAG	GTGTAGGAAT	18393
GAAAGTGAGT	GGGGAAAATT	ATCTCCAGCC	CTAGGGAAGT	CTGAGGCCTG	TGTCCCCTTT	18453
GTCTTGGA	GGGCCCCTGC	CTTGGGTGTC	TGTCCAGGGT	CTTTGCTCTA	CAGCCCCAGC	18513
GGATGCCCAA	AGTAGACGAG	TCAACTGGTC	CTTTCTTTCA	CCCTGTGTCC	ACTTCTCATG	18573
TATCTACCTT	CATAATCCTT	CTAGGTAAAA	CAAGCCTCTA	ACTTTGGGTT	TTCAAATCAG	18633
CCAGCTTCCA	GGCTCGATAG	TACGAACCAT	GAAAATCTTT	CTTACCATGA	GGTTGTTTTT	18693
TAGTGTGTGT	GTGTGTGTGT	GTGTGTGTGT	GTGTGTGTGT	GTGTGTGTAC	GTACACATAT	18753
GTACCTCTAT	CAGTGTGCTG	TGCGTGTACC	ACAGCAGACT	CGTGAGGAGG	TCAGGCAAAC	18813
TTTATAAAAA	TCTTTTTTTT	TTGCTTCACT	TGAGTCCCAG	GGTCACACAG	TGGCAAGTGC	18873
TGAGCTCTGT	TCTCTGTTCT	TGATTTGTTT	TGTGAGCAGC	TGATGTTCTT	AAGGCTTGCG	18933
GAGGGGAAAG	GTAGGGCTGG	CTTGCTTCTT	CCCCGAGTGG	CGGTCAATCC	CTAGACATCT	18993
CTAAGCCGTG	GCCACACGTC	CTGGAAGGAC	CCAGGTCAGA	AGTGATACTG	AGATGGCCCT	19053
GTGAGCCCTC	TCGAACACAC	AGGGTTGTAA	ATAGTACCTG	ATTGTTACAT	TGGAGACTCG	19113
TCAGCTGGGT	GGAGTCCTGG	TTCAGAGGGA	GTTATTCCCTC	CCCCCACATT	TCTTCTCTTC	19173
TGGGGCTGAA	GTCTCTTCCT	TCCTTACCTG	TGATGCTGTC	ATGATAGGTC	CCAGCTGAGA	19233
GTGGAGGCGG	GGCAGTCAGG	GAGCTGCTTC	TCTTTGCTTA	GCAGGGGTTG	GAGACTTGGG	19293
GTGTAGGGGT	TGGCTCCCCC	TTTCCCTGCC	CTGGACCTGG	TTTCTGGTTT	CAGCAGAGAT	19353
TCGTTCTAGA	AAC TTGTTGC	GTAAACAAGA	TCACAAAGCG	ATAAGCTTGA	GCAAAACCCA	19413
GGGGAACAAA	TTGCTTCCCT	GTGAAGACCC	AATCTTAGCT	CTTAGAGAAG	CCCTCCCTTT	19473
TGGAAATTGC	TGACTTTCAG	GGCTTCTCTG	TGGAGGAAAG	AGGCTAGCCG	CCGTATGTTT	19533
GCCTGGATTG	CAATAAATCT	TTGCGGCCTT	GGCTACCCCT	TGTTGAACAA	GGTCTGCACT	19593

CCTAATGCGT GCCTCAGGTG GTCTGAGACC TCTACCCCAT CTCCAGCTTT TCCTTCCTAT	19653
GGAGGGAGTC AGTGGGTTAG GAGAGAATGG AGTTGAGTCC TGGAAATGAGG AGGAAGCTAT	19713
GAACTCGGGG CCTGTTCTTG TCTGGTGGGT GCTCTTCTCC GCCGCTGAAG GAGGCAGCCG	19773
CAGGGAAGAC TACCACAGGA ATCCGAGTAC CACCTGGAGC AGTGTATACA GGATGTGGGC	19833
TGATGTGTGG TAAGGGCATG ATGGGCTGAT GTGTGGTAAG GGCATGGGAT CTGATTGCTC	19893
TGTGGATGGG CCACAGGGAA ATTTTGTAGT GTCTACTGCA GTAGTTCTCA ACCTGTGGGT	19953
TGTGCGCCCC TTGGTGGGAG TTACATATTA GATATTTACA TTATGATTCA TAACTGTAGC	20013
AAAATTACAA TTGTGAAAGA ACCAAGAAAT CACCGCAGCA TGAGAACCTG TATTAAAGGG	20073
TCACGGTGTT AGGAGGGTTG AGAGCCACTC ATCCTCTGGG TCTAGGCCAT GGCGGGCTGT	20133
AACTGCTCTC TGGAGTTAAG CCACAGTGAA CCAGCTGTCC TTGCAGATGG ACTTGTGGAG	20193
GCTCCAAACC TTTGTCCCAG GGGAGAAGAG CTTGCTTTTG CTTTGTACTT TTAAAGGAAG	20253
TTCAGTGGTC TTCGGGCCTT GTGGCTGCTG TGTGTGGAAG TGCCCCTGTA CAATAAGCTG	20313
TATAGATCGT GTACAACTGC AGTTTTCTC CGTGGGTCCA CCAACCACTC CTGACTCCAC	20373
GGATGAGTGA GGCCAGTAGG GCTGTGTGTG GGTCCCTAGG CCAAGCATCC TGGACCACGA	20433
TGAGCCTCAG CTAGACCACT CTGGATCTTT AGCAGAGGCT CCTAGAGAGC TGGCTGGCTT	20493
CCTCCTGCCT TCTTTTCTCT TAAAACTTCG TCTCAATCGG AAGCTCCTCT GTGCACGTGA	20553
CCTCCAGGCC TGGGGGTCGC CACAAATCCC CTCATCACAA GACGAGCAGC TCGCATGAGG	20613
GACACGACAC TTGTTACCTA CCAGGCTGTG GGGTTTTGT TGGTTGGTTG TTTTGTTTTG	20673
TTTTGTTTTT TTACTTGTA AGAAGTGTTG TGACATCAGA TGTCAGCTGT TAGTGCTGGC	20733
ACCATTTTAC AGGTAGGGAA CTGAGGCTGT AAGATGTGTA GTGACATCGC TAAGGCCACT	20793
CAGTTGGTGA GGCCTTACCA AGGTCAGGTC TTTGGAGCCT TTTGCTGAAC CATGTACTTC	20853
TATCTCTGTT TTGTTGAAAC AAAGTCTATA TGGCTCTGGC TAGCCTATAA CCCCATATGT	20913
AGACGAGGCT GACCTCGAAT ACACTGCAGT CTTTTATGTC TGCCTTCTGG GTGGCAGGAT	20973
TGAAGGCATG TGATTCCTCC TAACTGTACA CTTTAAAAA AAAATCATTC TTTGTTCTGG	21033
TCTGTGCCAG GGCCTTGTA GATGTTCTGT GCTGAGCTGG GCTATTTGGG TTAGTCTCAT	21093
TGCTGAGCAG GGCCCCTGTA TCTTCCTTCT CTGTCACTTG CTTACCTGGG TCTTCCTCCT	21153
GCACTAGCTA TCCTAGAACC AGTACTGAGA GCAACTATGG GCCCAACTCT GCCCCTTGCC	21213
CAGCCTGCTT AGCTGGGGGC GGTGTTCCAC TTCCCTGCCC AAGTCCTGTG GGA CTGTGTT	21273
TGTACTCCAC CACCTTCAGT TCCTTGAGC TGGAGCAGGC CAGGCGGCTG CATTCCTGCA	21333

GCTGCTGTTG	CCAGGGAGAG	CCCATCCCAT	TCACTTCAGT	CTCCTTAATG	TAGAAGCCTT	21393
GTCGAATTAG	CTTCCACTGT	CCCCAACCCA	AGAGTACCCT	GTCCTTTTCTT	CACTAAGAAG	21453
GCCAGGATAC	AGTCCTTCCT	GTGGCTGATA	AGACAGGCCT	TGGGACAAGG	CCTGGGACCA	21513
CACTGTGTGG	GCAAAGCTGC	TTCAGCACCG	ATGGCTCCTC	CATGCCAAGC	TTGGCTCTGC	21573
TTCTCACAGT	TGAGACTTCT	GTGCGCACAC	CCACTGTCTA	GCTCAGCTGG	AACTGATTT	21633
TCTTTAAATG	TATAGATTTT	GGGGTGGGGT	GTGCTGAAAG	CTCCCACTGA	TGCCCCAAGC	21693
CTGAGTCTCA	GAGTATGATC	AATTGATGGC	TTTCATGGGT	ATCACAGCTT	CTGTTCCCAG	21753
GTCAGACTCC	CTGACCAGTC	AGAGCATCCT	GGGGTTAGAC	AATGTCCCCG	TCACTTGTGC	21813
CTCCACCTGG	CACCAGGCTA	TGATGTTATG	GCATTGAGGG	TATGAGAAGG	ACCAGGGGTT	21873
TCCCAGAGTT	ACGCCCAGGC	GCACAGGCAA	TTGTTTCCTA	CATGTGTGGC	TGGAATGGTT	21933
GGGTGAGCCT	TTTCAGCTGC	CTACAATAGG	AACCCAGGGA	TACTGGGCAT	TGACCAAGGC	21993
ATATCTCATA	CCCTTTTCTT	ATCTTTCTGC	AG CAA ATT GTG GCT GTA AAT GTT			22046
			Gln Ile Val Ala Val Asn Val			25
CCT CCT GAA GAT CAG GAT GGC TCT GGG GAT GAC TCT GAC AAC TTC TCT						22094
Pro Pro Glu Asp Gln Asp Gly Ser Gly Asp Asp Ser Asp Asn Phe Ser						
30		35		40		45
GGC TCT GGC ACA GGTAAGACTG	ACCCAGAACA	CTGAGATGGC	ATAGATCATG			22146
Gly Ser Gly Thr						
GCTGGAGTGG	TGAGCAGGCA	GTCACCCAGC	TTTTAGTGAA	CCCCCTTCTT	CTCCCATCCC	22206
ATCCTTAGCC	ATTGGAGTCA	GGACAGTGCC	AAAAGGAAGA	ATGGTATCCA	GCTGCAAGCC	22266
ACTCAGCTAA	GAGAACTCT	CAGAGAAATG	AAGGGGTTC	ACCAGGCCAT	GGGCAGCCAC	22326
TAGAGCCAAC	CCTTGGAGGA	GTTTGACTCC	ACTGAGCCTT	GGTGTGGTGT	TTCCATCTGT	22386
GAGATGGGAA	TACTTTGCCC	AAGAGCCTGT	TAGAAGCTGT	AGGAAGCACA	GAGTCGGCTA	22446
GGTATAGATT	TGCTCTCACC	TCCATCTCTC	GATACCAGTT	CTCTGCAGAG	CTTGGGTTTG	22506
TGGGAGGGGT	GGGGGGGTGA	GGGGAGAAGG	CTGTGAGCTG	CAGCTAGCCA	GAGGGGTCTC	22566
CCAGAAGAAT	GGGGAGAGCT	AAGAAGGAAA	GTTGAGGTCA	CAGTGGGAAG	GAGACCAGAG	22626
CAAAGGGTTG	GAAGGTAGGT	AAAATGCAGC	CGTGTATTCT	TGGGAGCCTT	AGGCCTTGGG	22686
CAAGAGGGTA	GAAGAGGTGT	TTGTCCTGGG	CTGCAGTCCT	GTATCAGCTC	TGGTGTCTTG	22746
GCCCACGCTC	ACAGCAGGAT	CCCTTCCCAG	ATTCCCGAGA	ATTTCTCACA	GTTTCAGAGAG	22806
CACGCTACTT	GTAGGCAGGT	GAGGCTGCAA	AGGACAGCTT	TTCTGGCCTA	ATTTTCAAAG	22866

TGAGTTCAGC	CTTTGCTAGG	TCACCTTTGG	GGTCTCAGAA	GGCTTCAGCT	CCTGGTAGAG		22926									
CATGAATCAC	GTCAGGCGTG	ATGCTGGAGA	CCTCTCCTAC	CCTGACACCC	CAAACCCCCA		22986									
CCTCTGACCC	TGCA	GGT	GCT	TTG	CCA	GAT	ACT	TTG	TCA	CGG	CAG	ACA	CCT		23036	
		Gly	Ala	Leu	Pro	Asp	Thr	Leu	Ser	Arg	Gln	Thr	Pro			
		50					55					60				
TCC	ACT	TGG	AAG	GAC	GTG	TGG	CTG	TTG	ACA	GCC	ACG	CCC	ACA	GCT	CCA	23084
Ser	Thr	Trp	Lys	Asp	Val	Trp	Leu	Leu	Thr	Ala	Thr	Pro	Thr	Ala	Pro	
			65				70						75			
GAG	CCC	ACC	AGC	AGC	AAC	ACC	GAG	ACT	GCT	TTT	ACC	TCT	GTC	CTG	CCA	23132
Glu	Pro	Thr	Ser	Ser	Asn	Thr	Glu	Thr	Ala	Phe	Thr	Ser	Val	Leu	Pro	
		80					85					90				
GCC	GGA	GAG	AAG	CCC	GAG	GAG	GGA	GAG	CCT	GTG	CTC	CAT	GTA	GAA	GCA	23180
Ala	Gly	Glu	Lys	Pro	Glu	Glu	Gly	Glu	Pro	Val	Leu	His	Val	Glu	Ala	
	95					100					105					
GAG	CCT	GGC	TTC	ACT	GCT	CGG	GAC	AAG	GAA	AAG	GAG	GTC	ACC	ACC	AGG	23228
Glu	Pro	Gly	Phe	Thr	Ala	Arg	Asp	Lys	Glu	Lys	Glu	Val	Thr	Thr	Arg	
110					115					120					125	
CCC	AGG	GAG	ACC	GTG	CAG	CTC	CCC	ATC	ACC	CAA	CGG	GCC	TCA	ACA	GTC	23276
Pro	Arg	Glu	Thr	Val	Gln	Leu	Pro	Ile	Thr	Gln	Arg	Ala	Ser	Thr	Val	
				130					135					140		
AGA	GTC	ACC	ACA	GCC	CAG	GCA	GCT	GTC	ACA	TCT	CAT	CCG	CAC	GGG	GGC	23324
Arg	Val	Thr	Thr	Ala	Gln	Ala	Ala	Val	Thr	Ser	His	Pro	His	Gly	Gly	
			145					150					155			
ATG	CAA	CCT	GGC	CTC	CAT	GAG	ACC	TCG	GCT	CCC	ACA	GCA	CCT	GGT	CAA	23372
Met	Gln	Pro	Gly	Leu	His	Glu	Thr	Ser	Ala	Pro	Thr	Ala	Pro	Gly	Gln	
		160					165						170			
CCT	GAC	CAT	CAG	CCT	CCA	CGT	GTG	GAG	GGT	GGC	GGC	ACT	TCT	GTC	ATC	23420
Pro	Asp	His	Gln	Pro	Pro	Arg	Val	Glu	Gly	Gly	Gly	Thr	Ser	Val	Ile	
	175					180					185					
AAA	GAG	GTT	GTC	GAG	GAT	GGA	ACT	GCC	AAT	CAG	CTT	CCC	GCA	GGA	GAG	23468
Lys	Glu	Val	Val	Glu	Asp	Gly	Thr	Ala	Asn	Gln	Leu	Pro	Ala	Gly	Glu	
190					195					200				205		
GGC	TCT	GGA	GAA	CAA	GTGAGTGGCT	TTGCATTTCC	TGGGTGGCCA	CTAGTGCCTG								23523
Gly	Ser	Gly	Glu	Gln												
				210												
CACCTGGCCG	CCTAATGTCC	TCATTACAGT	GACAGGTGAC	AGGGTCCCAC	CTTCCTCCTG		23583									
CCCGAAACAG	ACTGATTGCA	AGATCAGGAG	GTGGGCGACT	CCTTAGATGT	CATTGAGGAG		23643									
CTTACAGCAG	GGTGAATTTT	CCGTCTTAGA	CCTTCATGGG	AATTTTCACA	CAACAATGTG		23703									
TACGTTGTGT	CACTGGAGGC	GGTATCTGTG	TCTTGGCCTG	CCAGGGTCCC	AGGTGTGACT		23763									
GACTGCATTC	CTTGACAGAT	GCTGGTATAG	GTTGGCTACG	TCTGATGGGG	GTGGCAGGGG		23823									

ATCCCATCAG GTATGGCACT GCTCAGGTTG CTGTTGTGTC AGTGGCTCCA GCTGACCTGA	23883
TCCCAACCTA CCCTTCTGTA G GAC TTC ACC TTT GAA ACA TCT GGG GAG AAC Asp Phe Thr Phe Glu Thr Ser Gly Glu Asn 215 220	23934
ACA GCT GTG GCT GCC GTA GAG CCC GGC CTG CGG AAT CAG CCC CCG GTG Thr Ala Val Ala Ala Val Glu Pro Gly Leu Arg Asn Gln Pro Pro Val 225 230 235	23982
GAC GAA GGA GCC ACA GGT GCT TCT CAG AGC CTT TTG GAC AGG AAG GAA Asp Glu Gly Ala Thr Gly Ala Ser Gln Ser Leu Leu Asp Arg Lys Glu 240 245 250	24030
GTG CTG GGA GGTGAGTCTT CTTTCAGGTG GAGAGGAGGA GGCAGGTGGT Val Leu Gly 255	24079
GGCTCTGAGG TAGCCTGGGT TGCTGGGGTG AAGCATCTTT AGCAGCAGGG TGGGGAAGGA	24139
GGAGGGTCAA TTCTACTCCA GGCCACCTCC TAGGCTGTCC GTCTAGTCTG GGAGAGACTA	24199
CCACTGACCC CGTGGAGCTA CTGATCTGAG CCTGCCTCTG TTCACTCCCT A GGT GTC Gly Val	24256
ATT GCC GGA GGC CTA GTG GGC CTC ATC TTT GCT GTG TGC CTG GTG GCT Ile Ala Gly Gly Leu Val Gly Leu Ile Phe Ala Val Cys Leu Val Ala 260 265 270	24304
TTC ATG CTG TAC CGG ATG AAG AAG AAG GAC GAA GGC AGC TAC TCC TTG Phe Met Leu Tyr Arg Met Lys Lys Lys Asp Glu Gly Ser Tyr Ser Leu 275 280 285	24352
GAG GAG CCC AAA CAA GCC AAT GGC GGT GCC TAC CAG AAA CCC ACC AAG Glu Glu Pro Lys Gln Ala Asn Gly Gly Ala Tyr Gln Lys Pro Thr Lys 290 295 300 305	24400
CAG GAG GAG TTC TAC GCC TGATGGGGAA ATAGTTCTTT CTCCCCCAC Gln Glu Glu Phe Tyr Ala 310	24448
AGCCCCTGCC ACTCACTAGG CTCCCCTTG CCTCTTCTGT GAAAACTTC AAGCCCTGGC	24508
CTCCCCACCA CTGGGTCATG TCCTCTGCAC CCAGGCCCTT CCAGCTGTTC CTGCCCCGAGC	24568
GGTCCCAGGG TGTGCTGGGA ACTGATTCCC CTCCTTTGAC TTCTGCCTAG AAGCTTGGGT	24628
GCAAAGGGTT TCTTGCATCT GATCTTTCTA CCACAACCAC ACCTGTTGTC CACTCTTCTG	24688
ACTTGGTTTC TCCAAATGGG AGGAGACCCA GCTCTGGACA GAAAGGGGAC CCGACTCTTT	24748
GGACCTAGAT GGCCTATTGC GGCTGGAGGA TCCTGAGGAC AGGAGAGGGG CTTGGGCTGA	24808
CCAGCCATAG CACTTACCCA TAGAGACCGC TAGGTTGGCC GTGCTGTGGT GGGGGATGGA	24868
GGCCTGAGCT CTTTGAATC CACTTTTCAT TGTGGGGAGG TCTACTTTAG ACAACTTGGT	24928

TTTGACATA	TTTTCTCTAA	TTTCTCTGTT	CAGAGCCCCA	GCAGACCTTA	TTACTGGGGT	24988
AAGGCAAGTC	TGTTGACTGG	TGTCCCTCAC	CTCGCTTCCC	TAATCTACAT	TCAGGAGACC	25048
GAATCGGGGG	TTAATAAGAC	TTTTTTTGTT	TTTTGTTTTT	GTTTTTAACC	TAGAAGAACC	25108
AAATCTGGAC	GGCAAAACGT	AGGCTTAGTT	TGTGTGTTGT	CTCTGAGTTT	GTCGCTCATG	25168
CGTACAACAG	GGTATGGACT	ATCTGTATGG	TGCCCCATTT	TTGGCGGCCC	GTAAGTAGGC	25228
TGGCTAGTCC	AGGATACTGT	GGAATAGCCA	CCTCTTGACC	AGTCATGCCT	GTGTGCATGG	25288
ACTCAGGGCC	ACGGCCTTGG	CCTGGGCCAC	CGTGACATTG	GAAGAGCCTG	TGTGAGAACT	25348
TACTCGAAGT	TCACAGTCTA	GGAGTGGAGG	GGAGGAGACT	GTAGAGTTTT	GGGGGAGGGG	25408
TGGCAAGGGT	GCCCAAGCGT	CTCCCACCTT	TGGTACCATC	TCTAGTCATC	CTTCCTCCCG	25468
GAAGTTGACA	AGACACATCT	TGAGTATGGC	TGGCACTGGT	TCCTCCATCA	AGAACCAAGT	25528
TCACCTTCAG	CTCCTGTGGC	CCCGCCCCCA	GGCTGGAGTC	AGAAATGTTT	CCCAAAGAGT	25588
GAGTCTTTTG	CTTTTGCAA	AACGCTACTT	AATCCAATGG	GTTCTGTACA	GTAGATTTTG	25648
CAGATGTAAT	AAACTTTAAT	ATAAAGGAGT	CCTATGAACT	CTACTGCTTC	TGCTTCTTCT	25708
TCTCTGGACT	GGTGGTATAG	ATATAGCCAC	CCTTTGCCCA	AACCCTGGTA	GCTCGGGGAA	25768
GCTTGGCTTA	AGGCTGCACG	CCTCCAATCC	CCCAAAGGTA	GGATCCTGGC	TGGGTCCAGG	25828
GTTCTCTGA	TTTATTTGGT	TTTGTGTGT	TGTGTGTGT	TTTTCTTTTG	GCTAAACTTC	25888
TTTTGGAAGT	TGGTAAGTTC	AGCCAAGGTT	TTACAGGCCC	TGATGTCTGT	TCTTCTAAAT	25948
GGTTTAAGTA	ATTGGGACTC	TAGCACATCT	TGACCTAGGG	TCACTAGAGC	TAAGCTTGCT	26008
TTGCAGGGCA	GACACCTGGG	ACAGCCTTCC	TCCCTCATGT	TTGCTGGGAC	ACTGCTGAGC	26068
ACCCCTTGCT	TACTTAGCTC	AGTGATGTTT	CAGCTCCTGG	CTAGGCTGCT	CAGCCACTCA	26128
GCTAGACAAA	AGATCTGTGC	CCTGTGTTTC	ATCCCAGAGC	TTGTTGCCAG	ATCACATGGC	26188
TGGATGTGAT	GTGGGGTGGG	GGTGGGGTCA	TATCTGAGAC	AGCCCTCAGC	TGAGGGCTTG	26248
TGGGACAGTG	TCAAGCCTCA	GGCTGGCGCT	CATTCATATA	ATTGCAATAA	ATGGTACGTG	26308
TCCATTTGGA	CAGCAGACAC	TTTGGTGTAC	TTGTGCAGTC	TCTTTTTTGGT	CTGGACCATG	26368
TCCAACCTCTA	TCTGGTTTTT	GGAATGGGAG	CCTAACTGGC	CTGTGTTCTG	GCTTGGTACC	26428
AAATAGCAAC	AGTCAGTGGC	ATCCTTGCCC	AGGCCCCAGG	GCAGGACTAT	GCTCTTGCCA	26488
TATCCAGGAC	TCCCGACTTT	GCACCTGTTT	TCCCTCTGTG	TGTAGCATCA	TGAACTCCAG	26548
CTAGGTTGTT	CCTTTCCCTG	GGGTCAGGAG	GATTCTGCTG	ACTCTGAATG	TCAGGATTTG	26608
CTTTTGTTCT	GTTTGCTTAT	TGGGCAATTC	TCAACCTTCA	CTAGCAACAG	TCTCATGTGT	26668

CAGGATTACA AGTATTGCTT GCACATTGAG GG

26700

(2) INFORMATION FOR SEQ ID NO: 2:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```

Met Arg Arg Ala Ala Leu Trp Leu Trp Leu Cys Ala Leu Ala Leu Arg
 1             5             10             15
Leu Gln Pro Ala Leu Pro Gln Ile Val Ala Val Asn Val Pro Pro Glu
          20             25             30
Asp Gln Asp Gly Ser Gly Asp Asp Ser Asp Asn Phe Ser Gly Ser Gly
          35             40             45
Thr Gly Ala Leu Pro Asp Thr Leu Ser Arg Gln Thr Pro Ser Thr Trp
          50             55             60
Lys Asp Val Trp Leu Leu Thr Ala Thr Pro Thr Ala Pro Glu Pro Thr
          65             70             75             80
Ser Ser Asn Thr Glu Thr Ala Phe Thr Ser Val Leu Pro Ala Gly Glu
          85             90             95
Lys Pro Glu Glu Gly Glu Pro Val Leu His Val Glu Ala Glu Pro Gly
          100            105            110
Phe Thr Ala Arg Asp Lys Glu Lys Glu Val Thr Thr Arg Pro Arg Glu
          115            120            125
Thr Val Gln Leu Pro Ile Thr Gln Arg Ala Ser Thr Val Arg Val Thr
          130            135            140
Thr Ala Gln Ala Ala Val Thr Ser His Pro His Gly Gly Met Gln Pro
          145            150            155            160
Gly Leu His Glu Thr Ser Ala Pro Thr Ala Pro Gly Gln Pro Asp His
          165            170            175
Gln Pro Pro Arg Val Glu Gly Gly Gly Thr Ser Val Ile Lys Glu Val
          180            185            190
Val Glu Asp Gly Thr Ala Asn Gln Leu Pro Ala Gly Glu Gly Ser Gly
          195            200            205
Glu Gln Asp Phe Thr Phe Glu Thr Ser Gly Glu Asn Thr Ala Val Ala
          210            215            220
Ala Val Glu Pro Gly Leu Arg Asn Gln Pro Pro Val Asp Glu Gly Ala
          225            230            235            240

```

Thr Gly Ala Ser Gln Ser Leu Leu Asp Arg Lys Glu Val Leu Gly Gly
 245 250 255
 Val Ile Ala Gly Gly Leu Val Gly Leu Ile Phe Ala Val Cys Leu Val
 260 265 270
 Ala Phe Met Leu Tyr Arg Met Lys Lys Lys Asp Glu Gly Ser Tyr Ser
 275 280 285
 Leu Glu Glu Pro Lys Gln Ala Asn Gly Gly Ala Tyr Gln Lys Pro Thr
 290 295 300
 Lys Gln Glu Glu Phe Tyr Ala
 305 310

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2196 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TCTAGAACAC TTATTAAGAG CCAGGCACTG AAAAGTGCAG ACTCCCTCAT TTCATCCTGG	60
CCGTGCTTAC AAGTAGTTTC CATGCTCTGG TAACCCTGTG CAGAGGGCAG CGTGGGAGGC	120
GGGCCGCTTG GTGGACGGTC ATGGGGGCTC TGCATGGGTG GTTGCCCTTG CCTCAGAAGA	180
ACTCCCTAAG TAAGAGCAAG TTAGCCTCCC TAACCCCTGG TGGGTTGTTG CTTCTTTTCT	240
CCTCTTGTTT CTGCCAAGAG AGGGTGGACC AAGAAGACCC CAGCCTACAG AACATGTGAT	300
CCAAATAAAC TTCTTTTCTAG TATAAATGTC CTAGCCTGTG ACGTTCTGGT AGACTAGCAC	360
AAGATGGACC AAGACAACCTC TCATCGAGAC TCTGAGGAAC GAACTGGCAT CACATGGGAA	420
CAGGAAATGA AGCTTAGAGA GAGGTTCTGT GGCTTGTTCCA ACATGGCTGT AGTTTAAATC	480
CAGCTTGCCA CCAAAGCACA CACATTTTAC TGCTGTGCTG GGCCGGGCCT CAGATCCCAG	540
GGGCTCCGGA GCTAGAAGGA CACGTGTATC AGCCATGGCT TCAGTTTATT GCTGTATACT	600
CTGTGCTTCT GGCTCTCATG GAAAAGACAG ACATTGGGGT TCTTATAATC TCTCCCTCTC	660
CCCTCCCCAC ACTCTATCCC CAAAGGAGGC ACCACTTCTG CAGGTAAATG TTATCTTCAA	720
AGCGCTCACA TCGCAACCTT TGCCACACACC ATCTCATTA AGGAATTGGC AGTGACTTTA	780

AGGTGAAAGA	ACTCGGTGGC	TACGTGTTAT	ATAAATTTGC	ATCTGGGTCT	CAGAGCTGGA	840
AGGAAGGCAC	TCCCATACAT	GCAGTCTGTA	CATGCAGTCG	GATGATGGAC	CAACAACACA	900
TTGTGATTTA	TGCCCCTGCT	GGTGAGCCCA	GGAATCCCTG	TAGCACTCTC	TCTCAGCTCT	960
AGGGCCCTGC	TTGTGTATGG	AAAACGCTTA	GTGTTTTATA	GGTATTTTGT	CAGAATACTT	1020
TAAGGAACTT	GACCAAAGTT	ACAGGGAGGT	TAGACAGATT	GTCATGGTAT	ACTCACCTCT	1080
GTCTCTGACC	CTCCTAACTG	GGACCTCTTT	AGTCTCCCTT	GAGGCAGGGA	GTGCCACATG	1140
CATGTGTCCA	GGCACATGTC	TCCTGGTTTA	CCTCCCAACG	CACCTCAAGT	CCCCAAGGTA	1200
GGTAGGCACT	TGTATTCTGT	AATTCAGAGA	GGCAAATCAA	ACTGTTACAA	TGTTTGCCCA	1260
AAGCTCCCCA	AGCAAAGTGG	CCCTAAGAGT	GAGCAAAGAG	ACTGCGTGCC	TTCACTGCCT	1320
GTGTGAATCC	CTGCAGATAG	TCTCTCATCT	TGGTGCCCTT	CCCACAGAGG	CTGGGGCGGC	1380
AGGAGGGAGC	CTGGACAGCT	CAGACACTGG	GTCATTGATG	ACTGTTGTGT	GGGATACCTG	1440
CCGGGGCGCA	GGAGTGAGCC	ATGCCACCCC	AGGAAGTGGT	TCAGGGTGAC	TCTTCTTGGC	1500
ACACCTGGGA	GGATGTAGCT	GGTGCTGGCA	CACCCACCGT	CACGAGAGCT	TCCTGTCCAA	1560
ACCTTCAACA	AAGGCGGCTT	CTTGAGACAG	GCTAGACTGA	AGTCACCAGC	CTTGGGTGGG	1620
GTCCACTATG	TAACCTCAGT	GCTCAGGAAC	CCTTTCCCAT	ACTGTCTGGA	ACTATACTGT	1680
ATGTAGCTGG	GTTTCCACGC	ATGTGTGCCT	GCACCCAGTC	CATCTCATCT	TCTATCTCCC	1740
TCCCCTTTCC	CGCTTCCCCC	CTCCCCACTC	TCCATCTCAT	CTTCCATCCC	CACCTCTTCT	1800
GGTCCCTGCC	CTGCTAAACT	CAGGGTAGCT	GCATTCCGCT	GGCCTTCCCC	ATGTTCCAGG	1860
CTTCAGTCCC	TTCTCTGCAC	CTGTCCTTTG	TGAAGTGACC	AGAGGATTTT	TGATCCTGTC	1920
TCTGTGCTC	TGAAGGGTCA	GGAGTTCCTC	CTGCCTGGAC	AAAGCCATCC	TGACGCACAT	1980
AAATAAAACA	AACATCAAAC	TCTATTCAAC	CCCCTGGAAC	CCGTGTGTGT	TACTTACAGG	2040
GCAAAAGAAT	GGAGCAGGGG	ATGGGTGTG	GGGGGGGGGG	GTGGCATCTG	GGTTGTCTAC	2100
AGTTGTGCAT	TAAGTTGTAA	TTAAGATGTG	CATTTCTCCA	AATAAGGGAA	AATTATTCTG	2160
GATTATTTGA	GTGAAGCTGA	AAGGTGATCA	TCTAGA			2196

WHAT IS CLAIMED IS:

1. A method of decreasing the growth of a malignant cell wherein said method comprises exposing said cell to efficacious levels of a compound that induces expression of syndecan in said cell.
2. The method of claim 1, wherein said induced expression is obtained by affecting the enhancer element of the syndecan gene (SEQ ID No. 3).
3. The method of claim 1, wherein said induced expression is obtained by affecting the suppressor element of the syndecan gene.
4. The method of claim 1,2 or 3, wherein said cell is steroid-responsive.
5. The method of claim 4, wherein said steroid is estrogen or androgen.
6. The method of claim 4, wherein said cell is selected from the group consisting of a malignant breast cell, an endometrium cell and a prostate cell.
7. The method of claim 6, wherein said method further comprises exposing said cell to an anti-steroid agent.
8. The method of claim 7, wherein said agent is toremifene or tamoxifen.
9. The method of claim 1,2 or 3, wherein said cell is a mesenchymal cell.
10. The method of claim 6 or claim 9, wherein said cell is a human cell.
11. The method of claim 1, wherein said cell is exposed to efficacious levels of a composition comprising growth factors of said cell.
12. The method of claim 11, wherein said growth factors are selected from the group consisting of bFGF; TGF- β ; and bFGF and TGF- β .
13. A method for treating a patient in need of treatment to decrease the growth of a malignant tumor in said patient, wherein said method comprises administering, to said patient, efficacious levels of a composition that induces expression of syndecan in the cells of said tumor.

14. A method of claim 13, wherein said composition affects the enhancer element of the syndecan gene.

15. A method of claim 13, wherein said composition affects the suppressor element of the syndecan gene.

16. The method of claim 13, 14 or 15, wherein said tumor is a tumor whose growth is stimulated by steroids.

17. The method of claim 16, wherein said steroid is estrogen or androgen.

18. The method of claim 17, wherein said tumor is selected from a tumor the group consisting of a breast, endometrium, prostate gland or mesenchymal tissue.

19. The method of claim 13, wherein said composition comprises an anti-steroid agent.

20. The method of claim 19, wherein said agent is toremifene or tamoxifen.

21. The method of claim 13, wherein the efficacious agents in the composition comprise growth factors.

22. The method of claim 21, wherein said growth factor is selected from the group consisting of bFGF; TGF- β ; and bFGF and TGF- β .

23. The method of claim 13, wherein said patient is a human.

24. A method of inducing differentiation of a cell to a more differentiated phenotype, wherein said method comprises exposing said cell to efficacious levels of a composition that induces expression of syndecan in said cell.

25. The method of claim 24, wherein the composition affects the enhancer element of the syndecan gene.

26. The method of claim 24, wherein the composition affects the suppressor element of the syndecan gene.

27. The method of claim 24, wherein the growth of said cell is stimulated by steroids.

28. The method of claim 27, wherein said steroid is estrogen or androgen.

29. The method of claim 24, wherein said cell is an epithelium cell.

30. The method of claim 29, wherein said epithelium cell is an epidermal skin cell.

31. The method of claim 24, wherein said cell is a human cell.

32. The method of claim 24, wherein said composition comprises an anti-steroid agent.

33. The method of claim 24, wherein the efficacious agent in said composition is toremifene or tamoxifen.

34. The method of claim 24, wherein the efficacious agent in said composition is a growth factor.

35. The method of claim 34, wherein said growth factor is selected from the group consisting of bFGF; TGF- β ; and bFGF and TGF- β .

36. A method of stimulating hair growth in an epidermal cell of skin, wherein said method comprises stimulating expression of syndecan in said cell.


37. The method of claim 36, wherein said stimulated expression is achieved by affecting the enhancer element of the syndecan gene.

38. The method of claim 36, wherein said stimulated expression is achieved by affecting the suppressor element of the syndecan gene.

39. The method of claim 36, wherein said cell is a mesenchymal cell.

40. The method of claim 36, wherein said method comprises administering a composition comprising efficacious levels of a growth factor.

41. The method of claim 40, wherein said growth factor is selected from the group consisting of bFGF; TGF- β ; and bFGF and TGF- β .

**Fig 1.**


**Fig 2.**

Fig 3.

-4138 tctagatattcaaaactcac cagatggagtgatgtccacc cctattgggtgggagtgacta
-4078 gtcttttctctgtcttctga ctgagatgcttagctagctc ttttaggacccaccctcacac ctgcaataataacttttattt
-3998 gctctcttagtacctttaac ccagtgagggttgacatgaga aattaactaccataatattat aatatttccatttcataaatg
-3918 aaaagtaaaataaattaaaa aaatagaaaggttttgagcatg atggccagtggttaaaggcc agtggctccaacgcaagtc
-3838 tgacaaatggtaacgggcct gttcttcaggcttgagggaat gtttattgattgaggctaaa agcaacccaaaggctccact
-3758 tgccatagtgtaagccctgg atgtgctctcccacactgca tggccacctgtggtgtcagc acctgggaagctgaggatga
-3678 tggggagtgccaaggtcatta gctacatagtataggctagc tgggggtacatgggtcacaaa aaagaaaaaaaataagcac
-3598 attgtaatcccagcacttga cagaccaatgggggggggat tgctgtgagtttaagacagc ctggcctacaaaagaaaaacc
-3518 ctacccaaacccaagaaaaa tgaaaccagtaataataaata gctattttcatttttaaatgc tctaagacacagcgttaac
-3438 acaaaagctctcgtctgtgg ttctattccctccttctcc cccaggtcttctttaaagtga tacttttgtttgtctattt
-3358 gcttgttttggatttttgct tttaaagacagggtctcact atytagctccaactatttgg gaactcactatgtagaccag
-3278 gctagccagggacttataga gatctacctaccactgectc ccaagtgtgagactaaagg catgtgacacttttgcttggg
-3198 tattacaaacattttaaaag aacattttgaacattaatag atgtatgtatatatactact ctatgtagtatatatgttag
-3118 acatttttccacttgagatac atatttactctcaaaataag ttttttgttttttttcttc ttttaaaatttattttattt
-3038 tttttttatttattttatta ttatatgtaagtacactgta gctgtcttcagacacnaccag aagagggagtcagatctgt
-2958 tacggatggttgtagcacc atgtggttgctgggattcga actctggaccttccgaagag cagtgggtgctcttaccaca
-2878 ctgagccatctcaccagccc cttaaatttatttttattctt atgtccattgggtgttttgcc tgcagtgtatgtgtaaaagt
-2798 tcagaaactgaagttacaga ctgttgtagctaccattgt tgtgggtgctgggacttgaa cctgggtcctctggaagagc
-2718 agtcattattcttaaccact gagccatctctctagccctc gtttttttagttttttttttt gttttgtttgtttttttgtt
-2638 tttttaagattttcttattt attatatgtaagtacactgt agctgtcttcagacactcca gaagagggcgccagatctcg
-2558 ttatggatggttgtagcac caigtggttgctgggaattg aactccagaccttgggaaga gcagtcagtgctcttaactg
-2478 ctgagccatctctccagccc cgtttttttaggttttgaag acagggtttcctgtgtagct ctatgtgtccaggaactagc
-2398 tctgtagaccaggttggcct caaatttagagatttgctg tctctctgctctctcagagc tgggattaaaagtgtgcagc
-2318 ccaacaatctactcaaagta ggttttgaaaagctttcca tattaggagttaactagctt catttcagaaatactgcatg
-2238 gaattcaaatgtgggaccat tcatagctactttgggtttc cttcagtgacaggcattcgg catgacctattaggggaagtca
-2158 aatggcctggagaagtcac ctgggtgagagggcgtatgc attttcagcttgacagacac tgtcaacctatgcagacagt
-2078 ctgctccagctcagatgtca attgcagtcagacctgcagt cagacgctaagctccctacc tactctccatcagcttagat
-1998 gtaaggggtgctggaacaaa ggctctctctctctctctct cctctctctctctctctctct ctctgtgaggatgttgtatc
-1918 ttttattttatgtaaatgg tacttcaactacatgtatgt cctgtgtgaggatgttgtatc tgatcctctggaagaatagt
-1838 acagctgtaagtcgccatac aggtgctgggaattgaaccc tcacaagccatgtagggtgc ccaataggagtcgtcttcg
-1758 ccatctctccaacctcttgc atattgaggacaggaggaat atgtgacctttcttgggtct ccctataggagtcgtcttcg
-1678 gaccatagcctcctttcttt agtgacctttcttgggtct cgtggtcatgtttaaaacat gctggtcatgtttaaaacat
-1598 tgatctgggctaaacttatg cagttggaaggaaagatcaa tgagaggacaggaaaggtaaa agatcccaaagccactgtgt
-1518 ctctctgttcccgctctcccc ccccccctcccgccccattt accaaagacctcaaggatct accaaagggagagtctctg
-1438 cctccaaatcatcagggtcaa aggactgaagagctgaactc cttgctattgggtattctttt accaagacctcaaggatct
-1358 ggtectaaagccttctgagc cttgctattgggtattctttt gacctagggcagctgagacg ccaaaagggagagtctctg
-1278 ctgtatgtagcccatagtta ggctactcgtggaggtgtgg tgtgtgtaaggaggtgtgt gagcctcagatctagcttct
-1198 caactgggtgctggttgttg tggggacttcccagagcgt ctatgcaggtgcaaagggctt cttatctgctctgcctgtagg
-1118 ccacagtgtagagtctacac gatgccatctatggccctgc cttctctcttgcctctgcgtg gccccatagagaatcatgaa
-1038 ggggctgaggaacaaggatg ttggaactgtgaggtccag tgcggtcacctggaacaaa gaggccatttattttttct
-958 agggcaagacagggtggtt tgggaaactgtgaggtccag gaaagacagcaaaaagaaa ataataataataataataat
-878 actgacacgtctgaaggagc tgcggtcacctggaacaaa ccagacagtgctcatgtctt taaaggtctttaaaggctg
-798 gctccgcagctggttaggcc tcccctatctcagcccggtg gggaggtgggaaccatacat gggaggtgggaaccatacat
-718 gaaggggctttctataaata ccgaggttgcctcccaaatc tttgtcacctggaggacccc tttgtcacctggaggacccc
-638 caataacaaagccagctctt gagaactaacatcgcccttc tccagggcagtgccctccgga tccagggcagtgccctccgga
-558 aaggaccaagacctcagggg gtcagctacgcatcaaggaa ggtgcgacgagggaattaca aagagtggggtgggcttga
-478 agctcactcgctgtggggc actcagacctgcaagagctg ggggtggggcgctccaagggg gggggcaaccagggggcg
-398 gcgctgcagcctcgacgta gctgggggtggggcggtagt tttgcaactgcagagcctt CGCAGAGGAAGGGACCTGGC
-318 gcgagtgacctgggtctcc CCAGAGGAGACAGAGCCTAA GGCAGAGGAGCTGGGACAGC
-238 gctcaggggagggaaggtgg gctgggggtggggcggtagt GGCAGAGGAGCTGGGACAGC
-158 ggtgtggctggatccctggg CCAGAGGAGACAGAGCCTAA GGCAGAGGAGCTGGGACAGC
-78 ggactaccagggcccgga GCTCGAGAGAGCAGCGAGCT GGCAGAGGAGCTGGGACAGC
3 CTCCGCGGGAGAGGTGCGGG GCAACCGGCACTCGGATCC ACGAAGCCACCGAGCTCCC
83 CGGCGAAACCTACAGCCCTC GCAACCGGCACTCGGATCC ACGAAGCCACCGAGCTCCC
163 GAGCCGCGCCGAGCTCCGT GCAACCGGCACTCGGATCC ACGAAGCCACCGAGCTCCC

Me

243 GAGACGCGCGCGCTCTGGC TCTGGCTCTGCGCGCTGGCG CTGCGCCTGCAGCCTGCCCT CCCGgtgagtggtggcccg.
tArgArgAlaAlaLeuTrpL euTrpLeuCysAlaLeuAla LeuArgLeuGlnProAlaLe uPro

323 gcagggtggtggaggcgccg gaagccgggactcgccactc gccgatgccatgcaggcgcc agcacgtggagggggagggg
403 agcggggacttcttccgcg ctgcctggcgatcctggga tggtagccctttaatgagg actcctgtcccaattcctct
483 acggctcgtggtatgccagga ggctatcccagctcgtggtc cggcgctcctgcagagtggg acctccattggttccccgct
563 cccaattaagtaaacgact ccacagggtctgagtcgcc ggcttaggcgctccgccc ccttaggcgcgcttggagt
643 tgctctctcccggtgctgtc ttgctggccatctcagcggc ctggcctccgccaagtgtccc ggaggatgcagtggccatgg
723 ccaacgccttttccataga ccctaattcaaaccagactg caggctgcacccccagcgcc gcggagtccggcgctcggc
803 cctttgcaacggggcaagtt tgggcacagcagagccggcg cggaacaggggggaagctga cgttcggggtggcgagggg
883 acgggattaaggctgtttgt gggacacaagagggtggctc agggacttcggtttttctct ggctgccccaggtagagccg
963 gccgagctggcagcgggagg ttccgggaagttggcttcag aacgctgaagaccctaagaa cccaactttggggtcgctga
1043 agttgtgctgccccggagg gcctcctccgcatggccgc gcgggggaccctccccgca gtggaccgggtacggctct
1123 tccccccccgactcggct ttgtgctgaagcgcgcgta ggggaaggcggtcccttggc ccgcccagtagggcgcggg
1203 gaaagaggagcgaacgtgga gctggcgactgggtggggaa gcttctgggtaggatgcagc catccactttgggtgggtc
1283 ggtctctctaatacagcggt tggcgacaaagagcttggtc gagggtacccagaaagtgc tctccgccccaaagccgccc
1363 tcgctagccgccttcccaa cggcgctttgttctcgccc cctgtaacccttccctggga accgccccgcagcgctggtc
1443 cttgacgtgggcccgggtcct gggtcgcccgccagtgccagc gctgcctccggtgtccacg ccctagccccgcacccgc
1523 tgtgaagtcccggtgtcct ttccactggcgctttgccc aacctggaaggcagaggcg aggtgaggagcctcaggctt
1603 tatcctcccggaagtggcag tctccaccgcacactctgg tctgcttaactcgatagtc tggcaaaaggcagacagtg
1683 cacagggaaggaggttggag cgctggtagataccaaggtc gtgtacaaataaagtggcac acgacacgtcccagtcact
1763 gttaatgcattgccttcgct ccttcccagggtgggtgggtc tctccatcactctggagccc aagagagggtcccataatt
1843 gtattgccatgagttgggg ttgtgtggggcgccaaatc aggggttctctgggagggcta tgaattccgaactgagtcct
1923 ctgtgcactcctggcttaa gggtcaagaaattgtttgag ggttgggtttttgtgggac tcagattatgctggaatca
2003 tagttaccactgtggagaag aaagtggagctacttagcat gcctccccggcgccctggc attacctccggtctgttct
2083 ctaggcccaacgtgaggcct cactggggcagtagagatgc actgtgaatttcttccag ccaggatctggagaggtggt
2163 gttctcttccctgggtgtct ttccggaacttctgtgtgct tgacctaaagccctcaagca cccattaataatgctgagta
2243 gacaactagaggtggcgctt tccggaacttctgtgtgct ggcctgggaggttgaacct ctaggaaacaggtctaggaa
2323 gtagaattatctcaatggaa ggcttctctggaggaagaaga tgagctgagccccagggtca ctgtctgagctttaggatca
2403 gactcccacttgaggcaag agtggtcgttttacttttt ttttaagttagtttatt tctcttaacagaaaacaa
2483 caaacaaaacaaaacaccc ccacattgttttaaaagtggg tgcataaagagttaggacata ttcagagcttccccctttcc
2563 tgaaaaatgaaggcagctgg gatttacttaaaatgagag acatatcacaattgccagag agcttggctcccttctcaggg
2643 ctccctaagctcctgtggga agcaggtcagacagccctgg ggaccagagagataggaggt gcttttgggtgcctgcctt
2723 gaatgggggaagggggggga gctgctgggatcagaggctg ctagcaactactccccagag actgaagcaggtttgtccct
2803 cagtgtcctgtggtcttctg tttctcctatatagaatagg agaaatgggtatttgcctg gaatagtgacttgcattttg
2883 ttcccttcttcttctctccc ttactgtaactcttggact agtagagacactttccccag gtcctggcagaattggaggga
2963 gtgggggagcctgtgcttg catgatgtcactgtggctt cagctctccaggagggtgg agttgggttgaacctactg
3043 tggctcttgatgggcccaca taaaacctcattaacacaca ttggtagggagaagggactg gaaagaatgatgggaaagat
3123 tgatgttttctcttttttt ttttttttttttggcagta ctttctagatctccccctcc ccttgcagcaaaaatttt
3203 ggattcctgaagtcctttga gaatgtataatggtagccag actttttttttttagtcag ctcaaaattgcctccttata
3283 aagtatccttgggtgttttt tgttgttgttgttgttgtg ttttgttttgttttaagaca aggtttctctgtatagtcct
3363 ggctgccctggaaactcaata tgtagaccaggtggcctca aactcaaagaaatccaccta ctctaaccttctcagtgctg
3443 gcctaaaggtgtaggccacc aaaagtgtcaacttttaca aagcagcttacttttagca ggattctgaaaccttattt
3523 ctttctgttatcttcaaca atacactgctaggtgtattt agtccctcatgatgctggg ctcctcaagtggcgccagggt
3603 caagcagctcctggttttt ggtggctctgaagaagactg tgtcccagtgactggcagtt tgaattcgagcttctctt
3683 tcttctcagctctttggcag gcagagtgcactgggtgtgc ccaagcctggagcttctctg ttaattctagtttatttc
3763 ttatcagactgaaaaacaa atcagggttgggtataattct tataaacacgaaggtctcac ctttgcgtacgtctccggt
3843 gtgtgggtctgatgtccctc gggaatctctgttgaggctg ctgcagtgtgtgtgctgta gaaagggcaaggtagaatgg
3923 acagaagcgtgctgccacc ccactgtcctgttcttaaat gatgaagcactggcccggtg aagagcctagagaactccct
4003 cggtgggagatgcacacaat gccaggaagcacacaggagc gtcttctcttgggtgacttt gaaggtccttgggtctgtt
4083 atcagctccagctgcctgg actaacaacaaaggctagct cactctcagtattgataatc gactctcctcaacttcaa
4163 gagactgatcctcactcggg agccttgaactcttagcaat tctcctgtctcaacttcaa agagctgaaattacagactc
4243 gagccaccatagcgactga aaccttgttcttaactcttg actgtgaactgactcttggg ttggtcttcttccatttct
4323 ttagtgatgttttagttcg cgtcctacataatctattgc ccatacttagaaacaacagg ttagagacagcattgggtcc
4403 agcagagcctcactgaag ctgagctcctgccactgatt accgtgtcagctcaagtga cacttccaactcctctgct
4483 ccccatctgtagagtagaca tcaccatactgtctcttct tgcagctcctgagcattt atgttcatttcataacgatg
4563 gtgcaaaagtgtttgttaag taaagtgtggggaatgtt gtaactttttatttagtg cttacttagctttctctct
4643 ctgttgtgtgtgggttggg tggggttttttagaggctt ggtagttttcttacttctt gctacttagctttctctct
4723 aagcctttatggtatgtatc attgcctgattgtttgagtg tgtgactgaggcacgcctg tgcatgtttgagagtagct
4803 tgtgcgtgctctcggtccta catatgtatggtgtgaatac actgtagagtgcaggccggc acactggggtgggtgaatc
4883 ctgtgagccctgcctggagt ttgcagatcttcttggaca ctectgtgtgagcatttt gtgtggagtgactgtttagc
4963 tggctgtagcctacattgtg ccttgggtaaaccttgagt attgggaaacacctgggct gctgagctggtgtggccgac
5043 gttccttgggtacagctaa aactcttcatgaaagttagt gctcacatgctattagtat gactgagctcaaggaaact
5123 gtcttgggtgtacgtgctt gccctctcatgcagtttatc tacagatttagtagagctt
5203 tgtcagccctgggaggtggg tttcgtggccacaagtgggt ttagcttggcaacacact tggcttctaggttgcatctt

5283 cctgtggttctttccaaggg aatgctaggggaacattttg gacattagattatttctagt cccaaagcacacagaacata
5363 ctgtttcctaattgcctttt ttttgttttctctcaatct ggttttgaagtgttgggtt gaaaattgccccctgagagc
5443 ctgccctagtgtgtgcagag ggaagatagtggaaacaggaa gtctgtagaagtatcttcc ttccaggacctgtgtcccc
5523 ggagcagagtgcagcatggtg tcatatcgcttttggctatt ccagaagagatgaggtttta ggtgagaatgaaccttttag
5603 aaccttctagaaccttctgt tgagtatgacaggaatgccc tgaatagggtccgaagtcca tggccactgtttgtctttt
5683 ccataagcaagcagcttcag gtacagacaataagactagg ttcttggagtgcagacctgc acttggtgccatttcagctc
5763 cagatggacactggaggtcc ctacacagcaggctctggga tggctggctttgctatgtac tgttgcctgctctacaagag
5843 cttcccaggttactagcctt tgcgcagctgggctcgctg gccaggcttgggcattggag aagggaacacttgccacctg
5923 gcataggctgtgtgttggga gagtgcaggaggtctggtgaa gcccgaagtggaggcaagt ttagtgggacttgaggagag
6003 ctcagttaggaaatctctggg ctagtgcaggcagggtgtgg tgggtgggtggcaggtggcgg gtctagatctccttttagag
6083 atttgcctagggtatcgctccc tgctgactctggaactcaga ggcctccagaggtgtctcct ctgggagcctctcaagggtc
6163 tcccactctctactgtttat ggctttgtgggtacctaataac tatatagagaagatatgttc ctctgcctccagcctggaa
6243 agttctgcccagtgactcac ctgagcctgcagccatgtgt gtacacaggcgtctcaggg gcttctgtcctgtggtctc
6323 agcctttctagcccgtgtg ttctcggcaggttagcatc tgggaaacccgggtcacctct tatttgcagctccctccctt
6403 tcttgggtgtcttccccctt ttaactactggtctgatggc cttagactcatgctgaaatt ctcttctttttgtcctagc
6483 cttgtctctgacttcttgtg atcctctgggctgtgaaat ccgctcaggggctccattt ctaacagtcacacactgggtg
6563 gagagaccgagtcctgggat ggtgaagctaacctgctgg gcttctcaagcttcaattgg ttctcttattctctctgg
6643 aggtactgctgccccaggg gaggctcagactagaccact ctggagtggaggtggggca ggttttcagatcagtgccct
6723 tggcattcgttggggaatg ggggtggatgggctctggg caaggctcaggctgggggtgg agggcagggtgatgttccg
6803 caccacacccaggcagcct ggcacctcccccaaggctccg ctcatcagcaggaatgaaag cagtgcggggcaggttggg
6883 cagtgggcagggtggcggtg ttatcgctgtgctcatcagc tgagtcacgatgccaggccc cacaagtcctcctggaggc
6963 tcacccacccaccttgacc caccagcaccactagcagg aggtagggcagggcagtgag acaagcagctcctgggggtc
7043 tgagaggcaaaggggagttg ttcatgacctgggtgtgcat ggggacttgtgggtgtctca gatattctgtgtccagga
7123 ggaagctgtcttaagtgcga acctgcctagagccctgct ggtgtcaggaaatgcacaag ggagagtgccatccatgga
7203 ataggcccatggagctagac cagtgcagtgacagtgaag tcagccccacctgtgtctt ccgagccagctggagggtt
7283 ttatctcagattctgcgaaa ccatagaatctagtcaggag cctagactgcaaagcaggct tctgtgatgtttaacttgc
7363 aggtctcctgggtatgaggg atacttagaaaggtcccga ggtaggggaggcatcaggaa gtagaagaggccaggcact
7443 tctatctcctgacttgcctc cttctccatctccaaggat ggtaaaaagaaccttccag tacactgacagagggaaaa
7523 ccttctcatctacccacttt ggaatctgtcgtatcagcatg tgcgtggcctgcttccatac cagaggtggctagagatgtt
7603 ccttgggaattcactgggtg gggacttgagtgtatcagag gggcacaagtaacattaac tctgggtatcctctgcagcaa
7683 atcggagatccccctctcta ggcgagttctcagtggtat tgggactcagggttgggcttg tagggccccagcaagagtcg
7763 ttgatgtcactccagcttct cccgaggaagatgaggggtgc tgtgttgggatcacatctct cctgaatggcatgttgggg
7843 agggatggagccctgtcttc tgaccctaaagcttggctt taggtggccacagtctctgg gttctgtcctacctccctgc
7923 ccttgtgtgcttcaaaggga gctctaaagggaactctcgcc attcgaatggcacagtgtt ccttctgttctcccacccc
8003 agaaggagcaggcctggat tgtagattcctagaagtaag tggcctgagcatgctgttg atgaacctggaaccaggcag
8083 gctgggcatcctaggacctg tctttccatagaagtctgaa tcagctaccttgggactg agtaagggtcctcacata
8163 tcagctggctagtccatctt ggctgatctaaaccacatta ggtgaagagaagcatgggt tacagtctgttccaccgaa
8243 ccacatactggctttatcag ttctcgtataattttgcagg taacttttagctctaagcc tgtctcctcatctgtgaaat
8323 cgggtccctcatcctctgcc tagaagggtcttggaaaga ttaatgaagttagtatgccga gtggttggggttctctcctt
8403 gactggagcaagtctctagg agtactaaggatagcctgct gtgtgcagcaccgccaggga ctgtgctgagtaggagggt
8483 acagagtcttcatgtgaatg gcccttctgggtcttgcctcg aagttagtgtgatgtcata gagtctacaacatgcctt
8563 tgtccttctcagaagtcca agccttctcctggcagaccag acattcatctccactgagcc tctatgtgagactggcctc
8643 ggctgagctgtgtgggctg agctggcgaatgggaaact agacacctgggcacctgggt gggggtcgggacagcagtg
8723 tttcagttgtaggcactgtg cccctgctggagcttctga ctgaaggttaccctgagagg aagcaggttccctatagaca
8803 ctaacatagctgggtcagag tgcaaggtgggtgtgccct gccctgaccattcagtgca aaggctgtcttctgggagt
8883 gagagctctgacaggactgt gatggcggagggtctcaga gcaaacctgctggcctctc cccactctgatggatatgtg
8963 ctcttaaacaagtgactgtc cactttgcctcaatttcaac atctgtaagatagataggc gttatggctgaaatgggt
9043 ttaaagattagtttagctaat acagggaaggtctctgaca cctacagccttggtcaggcc cttagggttctcccaccacc
9123 atttccaaaggtctcgacct gtccctatgcttcaagtgc tttcctttaagccacctctg cgtcaactctaaaaggcgtg
9203 cttggcccccaggacctagac tgctggacctgacccatt ctgggcccgtttgttctgtg cttagggttctcccaccacc
9283 ggagtgtttatctaggctg tgagggtgtcagagaaaggac ctgaggtctggcacctcag cttagccacctgtgtggga
9363 gaactgagaaacccacccac cttttcaaaaacagcctctt ctgaggtctggcacctcag tgcacaggcatcttagttc
9443 ccactcccagcatgctctgc ctttgggttgtttccaggg gctcagtgctttaaaga cacagaggctaaagaaattt
9523 aaggggaaagaggaaatgaa gtgtatttgcctgggtgggt attcctgtcacttgcattct cagggtccttcttagaat
9603 gctcttctgtatctttagtc tcttctttatgatctttcc catctgttgcataccactg ccttcccacaggcatttta
9683 tagccctcccccataggaa gccgacttatgtctataatgt gaatgacaagtatcctttag ccttcccacaggcatttta
9763 attttcaaaagggtcattgca caaccgcagagacactaaga agagagggttgggtgatcaga gttacagccccagcctcca
9843 gctggtggccggctgggtgc aggtgtgtcgaaagcagtag ggtgtcaggccccatatcc gaggatcctttatttagcca
9923 gttcaggggcggaatggcca tgcgaagtctatgtgtaca ggtgtcaggccccatatcc tgcgtagcttagaatcagct
10003 acgtgacagttttgggggta ttgccagactgggagtttac atccagaagcgagaatggt ggggttcttactgtctcca
10083 gacaggatctttcccccaag tttgtcagccacctctcttc aagtccttggctctgacca gcaagacgtatccaaagaa
10163 actgaggaggcccttcaact ctttttaggatagtggtggg ccagcatggtgggggtggg aatggcttctgtctcttc
10243 atcatcacaggctacttccc agagacacttgcattctggg catctccagcagtcacctgg ccccaatgcttctgtgccc
10323 tttgcttcagccactgtatc tgggtgtcccttgaagggtga gccagagctcctaggcagag agcatgtgtatataaagcc
10403 gtaggctgggcccctgggaac cttcttctgtctatctcct gtcaaacccctatggtatgg tagccacataaggcttgtg



10483 caaaaaaacaggccaaaacat aagtatcttttctactctat cgggtcttctcattttccca tggtagcttcggctggccag
10563 gcccaaaagatttgaagaga ggtggctggcaagtctaggg gaataggtctatctggttcc ctccaggagcagtgcttagt
10643 gagaggctgggctgggcagg gcagggccccttgcctcaca ttgcctgaagtcgccccctg cccgtcctggctgggatctg
10723 gcaggctctccagctccaca cccggctctcagctgagcct gctcagagactagtcctggc atgtgggttgccagggtggt
10803 tccagctccaccaggaggta tgggcgtctgggtactcatg ggacattgacctgtagtggg tatggagagtggaggaatgg
10883 tacaggcagggtgtgctggg ctgacggacttgactccggc attgacctggccttgagtc tgggtttaactaacaggga
10963 atgctgacaaaaagacagt tattaaaaccaagacaggat actgctttccactcagccc attcccaagaatcccaaga
11042 cgtacaggaaatgtgcaaca gcagtgggaattgctgagtt ggggatgtgggtgagctgt gtgctcccagggaattttgg
11123 gaaattccccctcctgtgaaa tgctgtcagggtctgagcct tggaggtgttttgggggtgc tgtgctccccagctaagcag
11203 ctaacagtcctctttacctg ccttgctcctcacttgcccc accctgggttgggcctctcg ttcactccctgctgggtcac
11283 cagtacttcagtgaggctct cagcttgattcttgggtggag agagagaaaagtgtgataaat ggggtgcctgtcagccggaa
11363 atttgggtgtgtcctgaagg caccaatgggggcccctccct ctggaggtggccttaggaa aggtttctgggtcttgagg
11443 cctccttacagtttcttagc tccatgggagagaagtgagg agttgggtatcgccacca gcatgaatctctggtcacct
11523 ctccagcatgcactgtccagc ctgatctttgagtgcataaa aagaacagaattatcctctc agagcacttcaattcccgcc
11603 agcacagtgggtacagagac aagctgcccagactcccagc gagggactagttgagcccca gcatgggactagttgagcta
11683 gacctgatacagtcaccagag agcctcgttgaggaaagctt gggaaaattcaccagcatt tccagccaggactggagga
11763 aggtgattatgggaaagaga gcagtcaagaccccaggctt taggacacaggatacaaaact gagagctaccgtagaggagt
11843 aggttttagtcacaatctct cctgtccgcccctaccctcca ggagacattgcacctgttag aacagctgccccggagtcca
11923 cctttgggccccctgggta gctcagtagtgtcagcatcc tctcattgacatcagtcagg ttacacagtggggcagctaa
12003 tgtgaaggcgctaggctggg aagccagctacttgggaaaa ctaggtgttctcctggtaggc cctagcaggaaggcagttcc
12083 tcttttcttgggtgctttaa ggggtctttggaagctttga atgttccctcagctcgttgg tgaagcaggccctcctggta
12163 ctgtggtgtttgtcttcgaa gagtgaaggcattggaagta ctaggtgatggggcgcttc caggatgctttgtctcttg
12243 cgctggccttacagagctctc ttgctacctagtccttgtag ttgtaacaccagattcagtc agggaaacaggagttagagtc
12323 ttgccttgctgagccctgc gcactgcaggaaaagactcc tctgagtggagcctttctc ctcagggtgactgctttcaa
12403 gtacagcagcctctgagggg gaagtgtcatttgacattgt ggtagtctctgggtccctg gatacagatgtcatgccag
12483 atcataggtctgtttgtaca gaggggaggcagttctgtag ctccagagtcctcagtaccc agagtgtgtgctctaggggt
12563 gagaggagaagactacagcc cttaaatcacaggtctgacc tgtgggtagggttagatctc ttgcatactatgaacctgtt
12643 tgaacccccctgggtatttgc tgtggaactagagctttggt tatcttgggtgtgactctcgg gtgtgactgaagcctgggt
12723 gtgggggtgggggatatgtc cctgtctttcccaatgtagt atgctgagtggacagagacc gggaatggctgtgaccagc
12803 cctggaacagggtgtgtgttg gtgggggtggggcgcaact atctgggatccagactgctt agttactcggtcccacca
12883 tcctttgataacagcagctc gtggcaccaggcagctgcag acggcccacaagtttgcctc gctttccactccacgaagg
12963 cagacgcccgggcttctgtt aattagagactgtgtagtg tttccctatacccactccc taggcttctctgggaaggc
13043 taagttcccagactgcccc tgtactgtgtgtgtgttctg ggaatccatttaatatcaaa tttcttacctggcttgacc
13123 ctggaatggggcactgggtg gtctgtatttttgaagtga tttgtctgtgtgtggacatg attctgtgaccttaaat
13203 tccaagtttccagggtgatga ttcatatgtacgcatatttt cctgcccgtgtgggtcctggg cttgtgggatcagaggaca
13283 tttcttttattatgtgtcat ccaaaagcttcttagggctg ggctttatcctgaaaataaa ggttcacagctggttaacat
13363 cttcagaaagtcaagttctct tgggaagccacaggcctctg tgcagggcggttagactcca gggtagcgggtaggtggcg
13443 aagtagacagccctgggat atcgcgagcgtcttgagat gccccttaggtatcatgatt ttgggtgtgtgacacagctga
13523 acagtgtcctggagtgtgta atcatgaagtgtcgggtgac agaccactctcagcctcagg cagccaggaccgggggtcc
13603 ttctctacaaaaaccttgta acagaggggtggccttccctc cgttcagtggtgggtgtggg gctggcagggaagtggctcca
13683 actgtcttcatactcaggat tgcccacagcccaaacatg tcttttggcaatggcttgca actagaggtgaactctctcc
13763 atcagattgagggtgactacc gctgtgcatctatataacc tttcacacgctgtatgggtg cccagcggcagctctggca
13843 ggtctccttttaagcatcctc ttctgtgtgtgaagctgtg gtaaagaaactgaggccatt ttcccttgagagagatggtc
13923 ttactatgtctgacccac ctggggagcccgaagaaag gatgtactacagttagtgga cactgttggctgatggcct
14003 gggtaagcactcatcttgt tgcctgtccagggtctttgc ttagagatgctgacctcagc aggactggaggaactgcatg
14083 tcagccagggtctttctcggc gtggggagcccgaagaaag agccctagggaagtctgagg cctgtgtccctttgtcctg
14163 tggtaggtccttcaccttg gctctgtcctctgtatatac ccttcataatccttctaggt ccaaaagcctctaactttg
14243 ggaggttaggaatgaaagt tccaggctcgatagtacgaa ccatgaaaatcttcttacc atagaggtgttttctagtgt
14323 ggtcctttctttcacctgt gtgtgtgtgtgtgtgtgtg gtagctacacatatgtacct ctatcagtgctgtgtcgtg
14403 ggtcctttctttcacctgt gaggtcaggcaaaactttata aaaatctttttttttgtct cacttgagtcagggtcac
14483 ggttttcaaactcagccagc ctgtctctgttctttagatt gtttgtgagcagctgagtg tcttaaggcttgccgagggg
14563 gtgtgtgtgtgtgtgtgtg tcttccccgagtgggcggtca atccctagacatctctaagc cgtggccacagctccggaa
14643 taccacagcagactcgtgag actgagatggcctgtgagc cctctcgaacacacagggtt gtaaatagtacctgattgtt
14723 acagtggcaagtgtgagct ggggtggagtcctgggtcaga gggagttattcctcccccca catttcttctcttctggggc
14803 aaaggtagggtggtgtgct cctgtgatgctgtcatgata ggtcccagctgagagtggag gcggggagcagtcaggagctg
14883 ggaccagggtcagaagtgat gttggagacttgggggtgtag ggttggctccccctttccc tgccttggaacctgggttctg
14963 acattggagactcgtcagct tagaaaacttgttgcgtaaac ttgagcaaaaacccaggga ttgctgactttcagggtctc
15043 tgaagtctcttcttctctta acccaatcttagctcttaga ccttggtaccccttggttga ccttggtaccccttggttga
15123 ctctcttcttcttagcaggg gcccgcgtatgtttgcctgg gcgtgcctcaggtggtctga ctttcttctctatggaggg
15203 gtttcacagagattcgttcc atggagttagtctggaat atggagttagtctggaat ggggctgttctgtctggt
15283 caaattgcttccctgtgaag gaaggaggcagccgaggga agactaccacaggaatccga gtaccacctggagcagtgta
15363 tctgtggaggaaagaggcta
15443 acaaggtctgcactccta
15523 agtcagtggttaggagaga
15603 ggggtgctcttccgcccgt


15683 tacaggatgtgggctgatgt gtggttaagggcatgatgggc tgatgtgtgtaagggcatg ggatctgattgctctgtgga
 15763 tggggccacagggaaattttt gagtgtctactgcagtagtt ctcaacctgtgggttggtcg ccccttgggtgggagttacat
 15843 attagatatttacattatga ttcataactgtagcaaaatt acaattgtgaaagaaccaag aaatcaccgcagcatgagaa
 15923 cctgtattaaaggggtcacgg tgttaggaggggttgagagcc actcatcctctgggtctagg ccatggcggggtgtaactgc
 16003 tctctggagtttaagccacag tgaaccagctgtccttgtag atggacttgtggagggtcca aacctttgtcccaggggaga
 16083 agagcttgcctttgtctttgt acttttaaggaagttcagtt ggtcttcgggccttggtggt gctgtgtgtggaagtgcacc
 16163 tgtacaataagctgtataga tctgtgtacaactgcagtttt cctccgtgggtccaccaacc actcctgactccacggatga
 16243 gtgaggccagtagggctgtg tgtgggtccctaggccaagc atcctggaccacgatgagcc tcagctagaccactctggat
 16323 ctttagcagaggctcctaga gagctggctggcttcctcct gccttcttttctcttaaaac ttcgtctcaatcggaagctc
 16403 ctctgtgcagctgacctcca ggcttgggggtcgccacaaa tccctcatcacaaagacgag cagctcgcatgagggacacg
 16483 acacttgttacctaccagggc tgtgggggtttttgtgtgtg gttgttttgttttgtttgt tttttactgttacagaagt
 16563 gttgtgacatcagatgtcag ctgttagtctgtggcaccatt ttacaggtagggaactgagg gctgaaagtgtgtagtga
 16643 tctgttaaggccactcagttg gtgaggccttaccagggtca ggtcttggagccttttgcct gaacctgtacttctatctc
 16723 tgttttgttgaaacaaagtc tatatggctctggctagcct ataaccatgtatgtagacga ggctgacctcgaaatacactg
 16803 cagtcttttatgtctgcctt ctgggtggcaggattgaagg catgtgattcctcctaactg tacactttaaaaaaaaaaatc
 16883 attctttgttctgggtctgtg ccagggccttgaagatggt ctgtgctgagctgggctatt tgggttagtctcattgtgta
 16963 gcaggggccctgtatcttcc ttctctgtcacttgccttacc tgggtcttctcctcctgacta gctatcctagaaccagact
 17043 gagagcaactatgggcccac cctgtcccttggcaggcct gcttagctggggggcggtgtt ccacttccctgcccaggtcc
 17123 tgtgggactgtgtttgtact ccaccaccttcagttccttg gagctggagcaggccaggcg gctgcattcctgcagctgct
 17203 gttgccaggagagcccacac ccattcacttcagttcctt aatgtagaagccttgtcgaa ttagcttccactgtcccccac
 17283 cccaagagtaccctgtcctt tcttactaagaaggccagg atacagctcctcctgtgggt gataagacaggccttgggac
 17363 aaggcctgggaccacactgt gtgggcaagctgtctcagc accgattggctcctccatgcc aagcttggctctgtctctca
 17443 cagttgagactctgtgtcgc acaccactgtctagctcag ctggacactgattttcttta aatgtatagattttgggggtg
 17523 ggggtgtgtgaaagctccca ctgatgccccaaagcctgagt ctacagatgtatcaattga tggctttcatgggtatcaca
 17603 gcttctgttcccagggtcaga ctccctgaccagtcagagca tctgggggttagacaatgtc cccgtcacttgtgcctccac
 17683 ctggcaccagggtatgatgt tatggcattgagggtatgag aaggaccagggttcccag agttacgccaggcgacag
 17763 gcaattgtttcctacatgtg tggctggaatgggtgggtga gccttttcagctgcctacaa taggaaccagggtactgg
 17843 gcattgaccaaggcatatct catacccttttcttattctt ctgcagCAAATTGTGGCTGT GlnIleValAlaVa lAsnValProProGluAspG
 18923 AGGATGGCTCTGGGGATGAC TCTGACAACCTTCTCTGGCTC TGGCACAGgtaagactgacc cagaacactgagatggcata
 InAspGlySerGlyAspAsp SerAspAsnPheSerGlySe rGlyThrG
 18003 gatcatggctggagtggtga gcaggcagtcacccagcttt tagtgaaccccccttcttctc ccatcccatccttagccatt
 18083 ggagtcaggacagtgccaaa aggaagaatggatccagctt gcaagccactcagctaagag aaactctcagagaaatgaag
 18163 gggttccaccaggccatggg cagccactagagccaaacct tggaggagtttgactccact gagccttgggtgtgggtttc
 18243 catctgtgagatgggaatac tttgcccagagcctgttag aagctgtaggaagcacagag tgggttaggtatagatttgc
 18323 tctacctccatctctcgat accagttctctgcagagctt ggggttctggggaggggtggg ggggtgaggggagaaggctg
 18403 tgagctgcagctagccagag gggctcctccagaagaatggg gagagctaagaaggaaagtt gaggtcacagtgagggaaggag
 18483 accagagcaaagggttgaa ggtaggtaaaatgcagccgt gtattcttgggagccttagg ccttgggcaagagggttagaa
 18563 gaggtgtttgtcctgggctg cagtcctgtatcagctctgg gttcttggcccacgctcaca caggatcccttcccagatt
 18643 cccgagaatttctcacagtt cagagagcacgctacttcta ggcaggtgaggtgcaaagg acagcttttctggcctaatt
 18723 ttcaaagtgtgtcagcctt tgctaggtcacctttggggg ctacagaaggcttcagctcct ggtagagcatgaaatcacgtc
 18803 aggcgtgatgtctggagacct ctccctaccctgacaccccaa acccccacctctgacctgc agGTGCTTTGCCAGATACTT
 lyAlaLeuProAspThrL
 18883 TGTCACGGCAGACACCTTCC ACTTGAAGGACGTGTGGCT GTTGACAGCCACGCCACAG CTCCAGAGCCCACCAGCAGC
 euSerArgGlnThrProSer ThrTrpLysAspValTrpLe uLeuThrAlaThrProThrA laProGluProThrSerSer
 19963 AACACCGAGACTGCTTTTAC CTCTGTCTGCCAGCCGGAG AGAAGCCCCAGGAGGGAGAG CCTGTGCTCCATGTAGAAGC
 AsnThrGluThrAlaPheTh rSerValLeuProAlaGlyG luLysProGluGluGlyGlu ProValLeuHisValGluAl
 19043 AGAGCCTGGCTTCACTGCTC GGGACAAGGAAAAGGAGGTC ACCACCAGGCCAGGGAGAC CGTGCAGCTCCCCATCACCC
 aGluProGlyPheThrAlaA rgAspLysGluLysGluVal ThrThrArgProArgGluTh rValGlnLeuProIteThrG
 19123 AACGGGCCTCAACAGTCAGA GTCACCACAGCCAGGCAGC GTGCACATCTCATCCGCAGC GGGGCATGCAACCTGGCCTC
 lnArgAlaSerThrValArg ValThrThrAlaGlnAlaAl aValThrSerHisProHisG lyGlyMetGlnProGlyLeu
 19203 CATGAGACCTCGGCTCCAC AGCACCTGGTCAACCTGACC ATCAGCCTCCACGTGTGGAG GGTGGCGGCACCTTCTGTCTAT
 HisGluThrSerAlaProTh rAlaProGlyGlnProAspH isGlnProProArgValGlu GlyGlyGlyThrSerValIl
 19283 CAAAGAGGTTGTCGAGGATG GAACTGCCAATCAGCTTCCC GCAGGAGAGGGCTCTGGAGA ACAAgtagtggtgctttgcat
 eLysGluValValGluAspG lyThrAlaAsnGlnLeuPro AlaGlyGluGlySerGlyGl uGln
 19363 ttcctgggtggccactagtg cctgcacctggccgctaatt gtcctcattacagtgcagg tgacagggtcccaccttctc
 19443 cctgcccgaacacagactgat tgcaagatcaggaggtgggc gactccttagatgtcattca ggagcttacagcagggtgaa
 19523 ttttccgtcttagaccttca tgggaattttcacacacaa tgggtacgttgtgtcactgg agccggtatctgtgtcttgg
 19603 cctgccagggtccagggtgt gactgactgcattccttgac agatgctgggtataggttggc tacgtctgatgggggtggca


19683 ggggatcccatcaggtatgg cactgctcaggttgcctgttg tgtcagtggtccagctgac ctgatcccaacctacccttc
19763 tgtagGACTTCACCTTTGAA ACATCTGGGGAGAACACAGC TGTGGCTGCCGTAGAGCCCG GCCTGCCGAATCAGCCCCCG
AspPheThrPheGlu ThrSerGlyGluAsnThrAl aValAlaAlaValGluProG lyLeuArgAsnGlnProPro
19843 GTGGACGAAGGAGCCACAGG TGCTTCTCAGAGCCTTTTGG ACAGGAAGGAAGTGCTGGGA Ggtgagtcttctttcaggtg
ValAspGluGlyAlaThrGl yAlaSerGlnSerLeuLeuA spArgLysGluValLeuGly G
20923 gagaggaggaggcaggtggt ggctctgaggtagcctgggt tgctggggtgaagcatcttt agcagcaggggtggggaagga
20003 ggagggtcaattctactcca ggccacctcctaggtgtcc gtctagtctgggagagacta ccactgaccccggtggagcta
20083 ctgatctgagcctgcctctg ttcactccctagGTGTCATT GCCGGAGGCCTAGTGGGCCT CATCTTTGCTGTGTGCTGG
lyValIle AlaGlyGlyLeuValGlyLe uIlePheAlaValCysLeuV
20163 TGGCTTTCATGCTGTACCGG ATGAAGAAGAAGGACGAAGG CAGCTACTCCTTGGAGGAGC CCAAACAAGCCAATGGCGGT
alAlaPheMetLeuTyrArg MetLysLysLysAspGluGl ySerTyrSerLeuGluGluP roLysGlnAlaAsnGlyGly
20243 GCCTACCAGAAACCCACCAA GCAGGAGGAGTTCTACGCCT GATGGGGAAATAGTTCTTTC TCCCCCACAGCCCTGCCA
AlaTyrGlnLysProThrLy sGlnGluGluPheTyrAla
20323 CTCACTAGGCTCCCACTTGC CTCTTCTGTGAAAAAATTCA AGCCCTGGCCTCCCCACCAC TGGGTCAATGCTCTGCAACC
20403 CAGGCCCTTCCAGCTGTTCC TGCCCGAGCGGTCCAGGGT GTGCTGGGAAGTGAATCCCC TCCTTTGACTTCTGCCTAGA
20483 AGCTTGGGTGCAAAGGGTTT CTTCATCTGATCTTTCTAC CACAACCACACCTGTTGTCC ACTCTTCGACTTGGTTTCT
20563 CCAAATGGGAGGAGACCCAG CTCTGGACAGAAAGGGGACC CGACTCTTTGGACCTAGATG GCCTATTGCGGCTGGAGGAT
20643 CCTGAGGACAGGAGAGGGGC TTCGGCTGACCAGCCATAGC ACTTACCCATAGAGACCGCT AGGTTGGCCGCTGCTGTGGTG
20723 GGGGATGGAGGCCTGAGCTC CTGGAATCCACTTTTCATT GTGGGGAGGTCTACTTTAGA CAACTTGGTTTTGACATAT
20803 TTTCTCTAATTTCTCTGTTT AGAGCCCCAGCAGACCTTAT TACTGGGGTAAGGCAAGTCT GTTGACTGGTGTCCCTCACC
20883 TCGCTTCCCTAATCTACATT CAGGAGACCGAATCGGGGT TAATAAGACTTTTTTTGTTT TTTGTTTTTGTTTTTTAACCT
21963 AGAAGAACCAAATCTGACG GCAAAACGTAGGCTAGTTT GTGTGTTGTCTCTGAGTTTG TCGCTCATGCGTACAACAGG
21043 GTATGGACTATCTGTATGGT GCCCATTTTTTGGCGGCCCG TAAGTAGGCTGGCTAGTCCA GGATACTGTGGAATAGCCAC
21123 CTCTTGACCACTCATGCCTG TGTGCATGGACTCAGGGCCA CGGCCTTGGCCTGGGCCACC GTGACATTGGAAGAGCCTGT
21203 GTGAGAACTTACTCGAAGTT CACAGTCTAGGAGTGGAGGG GAGGAGACTGTAGAGTTTTG GGGGAGGGGTGGCAAGGGTG
21283 CCAAAGCGTCTCCACCTTT GGTACCATCTCTAGTCATCC TTCTCCCGGAAGTTGACAA GACACATCTTGAGTATGGCT
21363 GGCATGTTTCCCTCCATCAA GAACCAAGTTCACCTTCAGC TCCTGTGGCCCCGCCCCCAG GCTGGAGTCAGAAATGTTTC
21443 CCAAAGAGTGAGTCTTTTGC TTTTGGCAAAACGCTACTTA ATCCAATGGGTTCTGTACAG TAGATTTTCAGATGTAATA
21523 AACTTTAATATAAAGGAGTC CTATGAACCTCTACTGCTTCT GCTTCTTCTCTCTGGACTG GTGGTATAGATATAGCCACC
21603 CTTTGCCCAAACCTGGTAG CTCGGGAAGCTTGGCTTAA GGCTGCACGCCTCCAATCCC CCAAAGGTAGGATCCTGGCT
21683 GGGTCCAGGGTTTCTCTGAT TTATTTGGTTTTTGTGTGTT GTGTTGTGTTTTTCTTTTGG CTAAACTTCTTTTGGAGTT
21763 GGTAAAGTTCAGCCAAGGTTT TACAGGCCCTGATGCTGTGTT CTCTAAATGGTTTAAGTAA TTGGGACTCTAGCACATCTT
21843 GACCTAGGGTCACTAGAGCT AAGCTTGCTTTGCAAGGCGAG ACACCTGGGACAGCCTTCCT CCCTCATGTTTGCTGGGACA
22923 CTGCTGAGCACCCCTTGCTT ACTTAGCTCAGTGATGTTCC AGCTCCTGGCTAGGCTGCTC AGCCACTCAGCTAGACAAAA
22003 GATCTGTGCCCTGTGTTTCA TCCAGAGCTTGTGCCCAGA TCACATGGCTGGATGTGATG TGGGGTGGGGTGGGGTCAT
22083 ATCTGAGACAGCCCTCAGCT GAGGGCTTGTGGGACAGTGT CAAGCCTCAGGCTGGCGCTC ATTATATAATTGCAATAAA
22163 tggtagctgtccatttggac agcagacactttggtgtact tgtgcagtcctcttttggte tggaccatgtccaactctat
22243 ctggttttttggaaatgggagc ctaactggcctgtgttctgg cttggtaccaaatagcaaca gtcagtggtcatccttgccca
22323 ggccccagggcaggactatg ctcttgccatatccaggact cccgactttgcacctgtttt ccctctgtgtgtagcatcat
22403 gaactccagctaggttgttc cttccctggggtcaggagg attctgctgactctgaatgt caggatttgccttttgttctg
22483 tttgcttattgggcaattct caaccttcactagcaacagt ctcatgtgtcaggattacaa gtattgcttgcacattgagg

Fig 4.

TCTAGAACAC TTATTAAGAG CCAGGCACTG AAAAGTGCAG ACTCCCTCAT TTCATCCTGG	60
CCGTGCTTAC AAGTAGTTTC CATGCTCTGG TAACCCTGTG CAGAGGGCAG CGTGGGAGGC	120
GGGCCGCTTG GTGGACGGTC ATGGGGGCTC TGCATGGGTG GTTGCCCTTG CCTCAGAAGA	180
ACTCCCTAAG TAAGAGCAAG TTAGCCTCCC TAACCCTGG TGGGTTGTTG CTCTCTTTCT	240
CCTCTTGTTT CTGCCAAGAG AGGGTGGACC AAGAAGACCC CAGCCTACAG AACATGTGAT	300
CCAAATAAAC TTCTTTTATG TATAATGTC CTAGCCTGTG ACGTTCGTGT AGACTAGCAC	360
AAGATGGACC AAGACAATC TCATCGAGAC TCTGAGGAAC GAACTGGCAT CACATGGGAA	420
CAGGAAATGA AGCTTAGAGA GAGGTTCTGT GGCTTGTTCCA ACATGGCTGT AGTTTAAATC	480
CAGCTTGCCA CCAAAGCACA CACATTTTAC TGCTGTGCTG GGCCGGGCCT CAGATCCCAG	540
GGGCTCCGGA GCTAGAAGGA CACGTGTATC AGCCATGGCT TCAGTTTATT GCTGTATACT	600
CTGTGCTTCT GGCTCTCATG GAAAAGACAG ACATTGGGGT TCTTATAATC TCTCCCTCTC	660
CCCTCCCAC ACTCTATCCC CAAAGGAGGC ACCACTTCTG CAGGTAAATG TTATCTTCAA	720
AGCGCTCACA TCGCAACCTT TGCCACACC ATCTCATTA AGGAATTGGC AGTGACTTTA	780
AGGTGAAAGA ACTCGGTGGC TACGTGTTAT ATAAATTTGC ATCTGGGTCT CAGAGCTGGA	840
AGGAAGGCAC TCCCATACAT GCAGTCTGTA CATGCAGTCG GATGATGGAC CAACAACACA	900
TTGTGATTTA TGCCCTGCT GGTGAGCCCA GGAATCCCTG TAGCACTCTC TCTCAGCTCT	960
AGGGCCCTGC TTGTGTATGG AAAACGCTTA GTGTTTATA GGTATTTTGT CAGAATACTT	1020
TAAGGAACTT GACCAAAGTT ACAGGGAGGT TAGACAGATT GTCATGGTAT ACTCACCTCT	1080
GTCTCTGACC CTCCTAATG GGACCTCTTT AGTCTCCCTT GAGGCAGGGA GTGCCACATG	1140
CATGTGTCCA GGCACATGTC TCCTGGTTTA CCTCCCAACG CACCTCAAGT CCCCAGGTA	1200
GGTAGGCACT TGTATTCTGT AATTCAGAGA GGCAAATCAA ACTGTTACAA TGTTTGCCCA	1260
AAGCTCCCA AGCAAAGTGG CCCTAAGAGT GAGCAAAGAG ACTGCGTGCC TTCCTGCCT	1320
GTGTGAATCC CTGCAGATAG TCTCTCATCT TGGTGCCCTT CCCACAGAGG CTGGGGCGGC	1380
AGGAGGGAGC CTGGACAGCT CAGACACTGG GTCATTGATG ACTGTTGTGT GGGATACCTG	1440
CCGGGGCGCA GGAGTGAGCC ATGCCACCCC AGGAAGTGGT TCAGGGTGAC TCTTCTTGGC	1500
ACACCTGGGA GGATGTAGCT GGTGCTGGCA CACCCACCGT CACGAGAGCT TCCTGTCCAA	1560
ACCTTCAACA AAGGCGGCTT CTTGAGACAG GCTAGACTGA AGTCACCAGC CTTGGGTGGG	1620
GTCCACTATG TAACCTCAGT GCTCAGGAAC CCTTTCCCAT ACTGTCTGGA ACTATACTGT	1680
ATGTAGCTGG GTTCCACGC ATGTGTGCCT GCACCCAGTC CATCTCATCT TCTATCTCCC	1740
TCCCCTTTCC CGCTTCCCC CTCCCCACTC TCCATCTCAT CTTCCATCCC CACCTCTTCT	1800
GGTCCCTGCC CTGCTAAACT CAGGGTAGCT GCATTCCGCT GGCCTTCCCC ATGTTCCAGG	1860
CTTCAGTCCC TTCTCTGCAC CTGTCTTTG TGAAGTGACC AGAGGATTTT TGATCCTGTC	1920
TCTGTGCTC TGAAGGTCA GGAGTTCCTC CTGCCTGGAC AAAGCCATCC TGACGCACAT	1980
AAATAAAACA AACATCAAAC TCTATTCAAC CCCCTGGAAC CCGTGTGTGT TACTTACAGG	2040
GCAAAAGAAT GGAGCAGGGG ATGGGTGTG GGGGGGGGGG GTGGCATCTG GGTGTCTAC	2100
AGTTGTGCAT TAAGTTGTAA TTAAGATGTG CATTCTCCA AATAAGGGAA AATTATTCTG	2160
GATTATTGA GTGAAGCTGA AAGGTGATCA TCTAGA	2196

*Fig 5A**Fig 5B*

**Fig 6.**

**Fig 7.**






Fig 8.

**Fig 9.**

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 93/00514

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K31/135 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CELL REGULATION vol. 2, 1991 pages 1 - 11 S. LEPPA ET AL. 'STEROID-INDUCED EPITHELIAL-FIBROBLASTIC CONVERSION ASSOCIATED WITH SYNDECAN SUPPRESSION IN S115 MOUSE MAMMARY TUMOR CELLS' cited in the application see the whole document ----	1,3-7,9, 10,13, 15-19, 23,24, 26-32
Y	PROC. NATL. ACAD. SCI. vol. 89, no. 3, February 1992 pages 932 - 936 S. LEPPA ET AL. 'SYNDECAN EXPRESSION REGULATES CELL MORPHOLOGY AND GROWTH OF MOUSE MAMMARY EPITHELIAL TUMOR CELLS' cited in the application see the whole document ----- -/--	1-6, 9-18, 21-31, 34,35

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 March 1994

Date of mailing of the international search report

28.03.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Hoff, P

Internal Application No

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter. Application No
PCT/83/00514

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J.E.F. REYNOLDS 'MARTINDALE, THE EXTRA PHARMACOPOEIA' 1989, THE PHARMACEUTICAL PRESS, LONDON see page 650 - page 651 see page 1625 ---	1-23
A	EP,A,0 462 398 (HOFFMANN-LA ROCHE) 27 December 1991 see abstract see column 1, line 52 - column 2, line 12; claims; example 2 ---	1-23
A	THE JOURNAL OF CLINICAL INVESTIGATION vol. 80, no. 5, 1987 pages 1516 - 1520 L. SCHWEIGERER ET AL. 'BASIC FIBROBLAST GROWTH FACTOR AS A GROWTH INHIBITOR FOR CULTURED HUMAN TUMOR CELLS' see the whole document -----	1-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 93/00514

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-41 are directed to a method of treatment of the human/
animal body the search has been carried out and based on the alleged effect
s of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
please see attached sheet ../...
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

2. OBSCURITIES,...

A compound cannot be sufficiently characterised by its pharmacological profile on its mode of action as it is done by the expression like "compound that induces expression of syndecan". Therefore the search was limited to the compounds mentioned in the claims 8,12,20,22,33,35,41.

INCOMPLETE SEARCH:

CLAIMS SEARCHED COMPLETELY: 8; 12; 20; 22; 33; 35; 41

" INCOMPLETELY: 1-7; 9-11; 13-19; 21; 23-32; 34; 36-40

INTERNATIONAL SEARCH REPORT

information on patent family members

Internat Application No

FI 93/00514

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9213274	06-08-92	AU-A- 9071391 EP-A- 0569367	27-08-92 18-11-93
EP-A-0335554	04-10-89	CA-A- 1325598 JP-A- 1287013 JP-C- 1770969 JP-B- 4060567 US-A- 5037643	28-12-93 17-11-89 30-06-93 28-09-92 06-08-91
EP-A-0455422	06-11-91	JP-A- 4224522	13-08-92
EP-A-0462398	27-12-91	US-A- 5147854 AU-B- 636489 AU-A- 7713991 CA-A- 2042973 JP-A- 5213772	15-09-92 29-04-93 12-12-91 23-11-91 24-08-93

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)